

University of California, Davis
IACUC Business Administration System

January 06, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M097, M222, M102, M111, M042, A095, M092, A019, M119, M087, A109, M110, M226, A013, M016, M024, M223, M001, M112, M114

Excused:

M009, M090, M004, M100, M093

Guests:

M224, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the November 18, 2021, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

The IACUC reviewed and approved the December 2, 2021, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

Sheep Barn Gates

Action: Retraining and follow up on security.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	12-17-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on BIO review and procedures. Additional discussion during the meeting included: a. None.			
2. # [REDACTED]	D Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI's response for dose in mg/kg. Additional discussion during the meeting included: a. Remains in DMR.			
3. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA and VHSS. Additional discussion during the meeting included: a. Remains in DMR.			
4. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA and VHSS. Additional discussion during the meeting included: a. Remains in DMR.			
5. # [REDACTED]	D Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending BIO			
6. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
7. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Correct species typo. b. Define acronym. c. references used as a guide for animal numbers supplied. d. Clarification of euthanasia procedure. e. Clarification of surgeons and surgeon qualifications.			

Additional discussion during the meeting included: a. None.			
8. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
9. # [REDACTED]	D Y	[REDACTED]	01-06-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Cheek swab DNA procedure clarification. b. Clarification on disposition. Additional discussion during the meeting included: a. None.			
10. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures. Additional discussion during the meeting included: a. Pending reviewer.			
11. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
12. # [REDACTED]	C	[REDACTED]	12-30-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of numbers and consent for non-UCD animals. Additional discussion during the meeting included: a. None.			
13. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
14. # [REDACTED]	C	[REDACTED]	01-05-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified fecal collection technique in cattle. Additional discussion during the meeting included: a. None.			
15. # [REDACTED]	C	[REDACTED]	12-22-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D		01-05-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending additional consult with CNPRC veterinarian.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending additional consult with CNPRC veterinarian.</p>			
2. #	C Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on feeding procedures and risk of copper exposure.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer approval of response.</p>			
3. #	C		01-04-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Biosafety confirmed BUA covers work and requested VHSS was attached to the protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending husbandry SOP.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
5. #	D Y		01-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Second reviewer approved at meeting.</p>			
6. #	D Y		01-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Modified to remove cautery or suture option.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	C		01-05-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	C		01-05-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	C		01-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	C		01-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of timeline.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D		12-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		01-05-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
14. #	C		12-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of Consent Form.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	E		01-06-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D Y		01-05-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Procedure details were clarified by PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on parameters for assessing pain/discomfort.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to DMR.</p>			
18. #	C Y		01-04-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	C		12-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of Consent Form.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		01-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		12-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of Consent Form.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	D Y		01-04-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Potential adverse acknowledged but not expected.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	D Y		01-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		12-17-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
25. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
26. #	C		01-06-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Details of the gait scoring provided. Additional discussion during the meeting included: a. None.			
27. #	D		01-06-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of **180** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	01-10-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal number justification, water regulation, pain management, and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to DMR.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
2. # [REDACTED]	D	[REDACTED]	01-07-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified injection volume and location.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>													

<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 19 </div>			
3. #	D Y		01-19-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending responses from PI regarding analgesic protocol and potential adverse effects. Additional discussion during the meeting included: a. Voted to send to DMR.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 19 </div>			
4. #	D		01-06-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. New VHSS added. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
5. #	D		01-06-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Surgery and post-surgery details clarified. Local anesthetic and analgesic congruent with 4th edition of Ag Guide. Additional discussion during the meeting included: a. Committee voted to approve.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
6. #	D		01-10-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 </div>			

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		01-09-2020	01-06-2022	01-09-2023
	C		01-21-2020	01-06-2022	01-21-2023
	D		01-09-2020	01-06-2022	01-09-2023
	D		01-09-2020	01-06-2022	01-09-2023
	C		01-08-2020	01-06-2022	01-08-2023
	C Y		01-09-2020	01-06-2022	01-09-2023
	C		01-09-2020	01-06-2022	01-09-2023
	D		01-09-2020	01-06-2022	01-09-2023
	C		01-09-2020	01-06-2022	01-09-2023
	C		01-09-2020	01-06-2022	01-09-2023
	C		01-09-2020	01-06-2022	01-09-2023
	C		01-13-2020	01-06-2022	01-13-2023
	D Y		01-09-2020	01-06-2022	01-09-2023
	D Y		01-08-2020	01-06-2022	01-08-2023
	B Y		01-09-2020	01-06-2022	01-09-2023
	D		01-18-2021	01-06-2022	01-18-2023
	D		01-13-2021	01-06-2022	01-13-2023
	D		01-21-2021	01-06-2022	01-21-2023
	C		01-08-2021	01-06-2022	01-08-2023
	D		01-21-2021	01-06-2022	01-21-2023
	C		01-21-2021	01-06-2022	01-21-2023
	D		01-21-2021	01-06-2022	01-21-2023
	E		01-21-2021	01-06-2022	01-21-2023

	D		1-08-2021	01-06-2022	01-08-2023
	D		1-21-2021	01-06-2022	01-21-2023
	D		1-10-2021	01-06-2022	01-10-2023
	B		1-08-2021	01-06-2022	01-08-2023
	E		1-21-2021	01-06-2022	01-21-2023
	C		1-21-2021	01-06-2022	01-21-2023
	C Y		1-21-2021	01-06-2022	01-21-2023
	D		1-21-2021	01-06-2022	01-21-2023

Discussion:	<p>Study method including varied temperature ranges needs to be included in section 9.</p> <p>Permit information on protocol is expired. PI provided updated permit information.</p> <p>Discussed study and funding source for larger discussion on under what circumstances UCD will review protocols or provide a letter of ethical review. One staff member on protocol has an expired OHSS and has not started renewal process.</p>										
Action Items:	<p>- Committee approved copy and pasting wording from section 14a to section 9.</p> <p>- Committee approved updating the protocol with the new permit information.</p> <p>- Committee to continue larger discussion about when UCD will have oversight over a study. Protocol will be deferred to the next meeting so staff member has an up to date OHSS.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved				
1. #	D Y		01-06-2022				
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of transport, analgesia, and monitoring for adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr></table>				IACUC Vote		Approval	19
IACUC Vote							
Approval	19						

<div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 19</div> </div>			
2. # [REDACTED]	D Y	[REDACTED]	01-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Discussion about chemical safety review and larger topic of VHSS. IACUC Director and AV to schedule meeting with chemical safety office to update VHSS criteria. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Committee voted to approve amendment with VHSS for Flavopiridol. <div> <div>IACUC Vote</div> <div> <div>Approval 20</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 20</div> </div> </div>			
3. # [REDACTED]	E	[REDACTED]	01-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification on anesthetic rates. Also, pending BIO and CHEM. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Voted to DMR. <div> <div>IACUC Vote</div> <div> <div>Approval 0</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 19</div> </div> </div>			
4. # [REDACTED]	C	[REDACTED]	01-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Reviewed objectives and amendment original protocol and committee agreed the amendment was supportive to overall study. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Committee voted to approve the amendment. <div> <div>IACUC Vote</div> <div> <div>Approval 19</div> <div>Withhold Approval 0</div> <div>Abstain 1</div> <div>Present 20</div> </div> </div>			
5. # [REDACTED]	D Y	[REDACTED]	01-06-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
6. #		C	01-07-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed adverse effects and dosages. Additional discussion during the meeting included: a. Pending PI.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 08-16-2021	
2. 08-20-2021	
3. 08-30-2021	
4. 09-01-2021	
5. 09-23-2021	
6. 09-28-2021	
7. 10-01-2021	
8. 10-19-2021	
9. 11-22-2021	
10. 11-30-2021	

Discussion:	9. Most of the deficiencies were related to building wear and tear. The SIC noted almost all building repairs have been completed. No animal welfare issues. Facility TIC left UCD and IACUC system as been updated with new manager information.										
Action:	9. Committee approved proposed plan to correct remaining deficiencies.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>14</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>14</td></tr> </tbody> </table>		IACUC Vote		Approval	14	Withhold Approval	0	Abstain	0	Present	14
IACUC Vote											
Approval	14										
Withhold Approval	0										
Abstain	0										
Present	14										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
-----------------	------	----------------------

1. 10-17-2020	LAB	
2. 07-22-2021	LAB	
3. 07-30-2021	LAB	
4. 08-03-2021	LAB	
5. 08-19-2021	LAB	
6. 08-25-2021	LAB	
7. 08-31-2021	LAB	
8. 09-08-2021	LAB	
9. 09-23-2021	LAB	
10. 09-23-2021	LAB	
11. 09-28-2021	LAB	
12. 10-07-2021	LAB	
13. 10-07-2021	LAB	
14. 10-07-2021	LAB	
15. 10-08-2021	LAB	
16. 10-08-2021	LAB	
17. 10-08-2021	LAB	
18. 10-08-2021	LAB	
19. 10-08-2021	LAB	
20. 10-19-2021	LAB	
21. 10-21-2021	LAB	
22. 10-21-2021	LAB	
23. 10-21-2021	LAB	
24. 10-29-2021	LAB	
25. 11-01-2021	LAB	
26. 11-03-2021	LAB	
27. 11-29-2021	LAB	
28. 11-30-2021	LAB	
29. 11-30-2021	LAB	
30. 12-03-2021	LAB	
31. 12-15-2021	LAB	
32. 09-23-2021	PAM	
33. 12-15-2021	PAM	

Discussion:	33. Request from other UC for vehicle inspection prior to transporting animals from their institution to UCD. The PAM was used to document the inspection for all of the criteria outlined on the other institutions vehicle inspection form.										
Action:	33. Committee approved the PAM as documentation for the vehicle inspection.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>16</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. IACUC Policy-13 "Transporting Research and Teaching Animals"	
Discussion:	Discussed adding an information about an emergency plan.
Action:	Approved after additions.
2. IACUC Policy-29 "Expired Drugs and Medical Materials"	
Discussion:	None.
Action:	Approved.
3. IACUC Policy-30 "Anesthesia Machine/Vaporizer Calibration, Use, and Maintenance Guidelines"	
Discussion:	Discussed canister weight clarification.
Action:	Approved.
4. IACUC Policy-41 "Guidelines for Changes in the Use of Therapeutic Drugs on Approved IACUC Protocols"	
Discussion:	None.
Action:	Approved.
5. IACUC Policy-43 "The Use of Prolonged Physical Restraint in Non-sedated Research and Teaching Animals"	
Discussion:	Discussed addition of teaching.
Action:	Approved.
6. Psychology Scientist-in-Charge: [REDACTED] for [REDACTED]	
Discussion:	None.
Action:	None.
7. SOP for [REDACTED] LAGO Imager.	
Discussion:	Additional information needed.
Action:	Tabled
8. IACUC training update	
Discussion:	Update on members still needing to finish ALL course.
Action:	8 remaining members to complete the course ASAP.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

January 20, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M111, M042, A095, M004, M092, A019, M119, M087, A109, M110, M226, M093, A013, M016, M024, M223, M001, M112, M114

Excused:

M222, M102, M090, M100

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:	
██████	- DI pump
Action: Pump failure; repair within 2-3 hours. No animal welfare concerns.	
Staffing issues	
Action: No animal welfare concerns but some units reporting workload issues related to policies and guidelines.	
██████	██████
Action: Complication during anesthesia. IACUC staff and/or CVS to observe next event.	
Electrical Issues CNPRC	
Action: Aging infrastructure.	

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
----------	----------	-------	---------------

1. # [REDACTED]	D Y	[REDACTED]	01-18-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI provided drug dosages in mg/kg.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA and VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
3. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA and VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
4. # [REDACTED]	D Y	[REDACTED]	01-18-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarified genotype/phenotype expectations</p>			
5. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of study design.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer.</p>			
6. # [REDACTED]	D	[REDACTED]	01-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Correct species.</p> <p>b. clarify acronyms.</p> <p>c. clarification of references.</p> <p>d. Add surgeons and their training.</p> <p>e. Clarify euthanasia method.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI Meeting</p>			
8. # [REDACTED]	C	[REDACTED]	01-11-2022

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
10. #	D		01-10-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers, procedures and water regulation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D		01-11-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified sedation and aspiration volume.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		01-07-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified injection location, volume, and precautions.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	D Y		01-19-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI clarified procedures, analgesia, and chem safety verified after further review no VHSS is required.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	C		01-18-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D		01-10-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			

17. # [REDACTED]	C	[REDACTED]	01-20-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Minor procedure clarifications.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	01-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	01-19-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified procedure and veterinarians performing biopsies.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	01-05-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response on regulation procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers and groups.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	C Y	[REDACTED]	01-14-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify feeding.</p> <p>b. Clarified copper toxicity is not concern due to short duration.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	C	[REDACTED]	01-20-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. None.			
6. #	C		01-20-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
7. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. CVS reviewing proposed SOP. Additional discussion during the meeting included: a. Remains in DMR.			
8. #	D		01-18-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
9. #	C		01-19-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
10. #	D		01-20-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified injection site and cell type. Additional discussion during the meeting included: a. None.			
11. #	D Y		01-20-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. clarification of adverse effects. Additional discussion during the meeting included: a. None.			
12. #	C		01-13-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
13. #	D		01-05-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
14. #	E		01-20-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #			01-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D		01-05-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	C		01-20-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	E		01-05-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	E		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on drug dosages, compounds and anesthetics.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	E		01-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		01-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on parameters for assessing pain and discomfort.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	C		01-20-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		01-20-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D		01-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed volume of saline.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	E		01-07-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified frequency of drug.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	D		01-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	C		01-19-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	C		01-19-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D Y		01-19-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. #	C Y		01-20-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	D		-

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI, and location of alternative space			
33. #	C		01-19-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
34. #	C		01-07-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified sedation-agitation scoring system and dosages. Additional discussion during the meeting included: a. None.			
35. #	C		01-19-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
36. #	D Y		01-06-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 295 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	01-20-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

2. # [REDACTED]	D	[REDACTED]	02-07-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of location and off-site vet client consent. Additional discussion during the meeting included: a. Pending. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
3. # [REDACTED]	D	[REDACTED]	01-20-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Procedure clarifications addressed by PI. Chemical safety completed review and provided VHSS. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
4. # [REDACTED]	D	[REDACTED]	01-20-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
5. # [REDACTED]	D Y	[REDACTED]	04-07-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Requested MOU. Additional discussion during the meeting included: a. Pending MOU.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
6. # [REDACTED]	C Y	[REDACTED]	02-03-2022										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Procedure clarifications associated with blood collection.

Additional discussion during the meeting included:

- a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		01-23-2020	01-20-2022	04-27-2022
	D Y		01-23-2020	01-20-2022	01-23-2023
	C		01-28-2020	01-20-2022	01-28-2023
	D Y		01-23-2020	01-20-2022	01-23-2023
	C		01-08-2020	01-20-2022	01-08-2023
	D		01-23-2020	01-20-2022	01-23-2023
	D Y		01-16-2020	01-20-2022	01-16-2023
	C		01-23-2020	01-20-2022	01-23-2023
	D		01-23-2020	01-20-2022	01-23-2023
	D		01-23-2020	01-20-2022	01-23-2023
	D		01-24-2020	01-20-2022	01-24-2023
	D		01-23-2020	01-20-2022	01-23-2023
	C Y		01-27-2020	01-20-2022	01-27-2023
	C		02-04-2020	01-20-2022	02-04-2023
	C		01-23-2020	01-20-2022	01-23-2023
	C		02-04-2020	01-20-2022	02-04-2023
	D		01-25-2021	01-20-2022	01-25-2023
	D		01-25-2021	01-20-2022	01-25-2023
	D		02-02-2021	01-20-2022	02-02-2023

	D		02-04-2021	01-20-2022	02-04-2023
	C		02-03-2021	01-20-2022	02-03-2023
	D Y		02-04-2021	01-20-2022	02-04-2023
	D		01-25-2021	01-20-2022	01-25-2023
	B		01-25-2021	01-20-2022	01-25-2023
	D		01-29-2021	01-20-2022	01-29-2023
	C		02-04-2021	01-20-2022	02-04-2023
	D		02-04-2021	01-20-2022	02-04-2023
	C		01-21-2021	01-20-2022	01-21-2023
	D		02-04-2021	01-20-2022	02-04-2023
	D Y		01-26-2021	01-20-2022	01-26-2023
	D Y		01-22-2021	01-20-2022	01-22-2023
	B		02-04-2021	01-20-2022	02-04-2023
	D		02-04-2021	01-20-2022	02-04-2023
	C		02-04-2021	01-20-2022	02-04-2023
	C		01-22-2021	01-20-2022	01-22-2023
	B Y		02-04-2021	01-20-2022	02-04-2023
	D		01-26-2021	01-20-2022	01-26-2023
	D		02-04-2021	01-20-2022	02-04-2023
	C Y		02-04-2021	01-20-2022	02-04-2023
	C		02-04-2021	01-20-2022	02-04-2023
	D		02-04-2021	01-20-2022	02-04-2023
	B Y		02-04-2021	01-20-2022	02-04-2023

Discussion: [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] one staff member on protocols is on last step of OHSS renewal process.
[REDACTED] -one staff member has not started OHSS renewal process.
[REDACTED] -IACUC director working with PI on submitting an amendment with updated literature search for approved amendment.

	-information in section 9 reads as food scheduling, not regulation. -study area moved in building. IACUC staff working with PI to amendment location on protocol. -chemical safety review inadvertently missed during original review. IACUC staff working with chem safety to ensure a VHSS is not required.										
Action Items:	-committee approved renewals. -committee requested removing staff member, informing PI of removal and staff cannot work under protocol until OHSS process is up to date and added back to protocol. -committee approved renewal. -committee approved removing wording from section 9 and adding to section 7. -committee approved renewal. -committee approved renewal.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	C	[REDACTED]	01-20-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D	[REDACTED]	01-20-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed review and provided an updated VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
3. # [REDACTED]	D Y	[REDACTED]	04-25-2022										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify number of animals and max timeline. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
4. #	D Y		01-20-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
5. #	C		01-20-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Inspection completed and SOPs reviewed of proposed temporary location to completed study groups. Provided facility manager with recommendations for making this area appropriate for the PI to conduct studies in this area. After discussion of options and current biosecurity concerns, it was agreed this was the best temporary solution. Additional discussion during the meeting included: a. Committee voted to approve amendment.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
6. #	D Y		01-20-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Add changes to criteria to use for discontinuing the affective touch. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
7. #	D		01-20-2022										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

8. # [REDACTED]	C	[REDACTED]	01-20-2022
-----------------	---	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

9. # [REDACTED]	D	[REDACTED]	01-20-2022
-----------------	---	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Discussed tissue adhesive.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 07-13-2021	[REDACTED]
2. 08-18-2021	
3. 09-28-2021	
4. 09-30-2021	
5. 01-10-2022	
6. 01-10-2022	
7. 01-19-2022	


Discussion: 6. Deficiencies due to staffing and supply shortages.

Action: 6. SIC has authorized hiring 2 student employees and an order has been placed for more supplies. In the interim, supplies may be hand washed with quarterly QA testing.

IACUC Vote

Approval	20
Withhold Approval	0
Abstain	0
Present	20



XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol	
1. 07-15-2021	LAB		
2. 07-22-2021	LAB		
3. 07-26-2021	LAB		
4. 11-01-2021	LAB		
5. 12-17-2021	LAB		
6. 11-29-2021	PAM		
Discussion:	None.		
Action:	None.		

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic
1.  PI maintain request
Discussion: Reviewed current buildings renovation project and request for specific study to move out now as the potential start date of the current buildings plan to move animals out would disrupt the study design.
Action: Committee approved PI maintain request.
2. ALL course - 100% completion!
Discussion: Great job everyone!
Action: None at this time. Future CEUs to be determined.
PI Maintained Form- 
Discussion: None.
Action: Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

February 03, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M222, M111, M042, A095, M092, A019, M119, M087, A109, M110, M093, A013, M016, M024, M223, M001, M114

Excused:

M102, M090, M004, M226, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

Hacking attempts/security changes

Action: Security updates from IT.

PETA lawsuit status

Action: Court ruling in support of UCD practices.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending final BUA approval. VHSS completed and attached to protocol. Additional discussion during the meeting included: a. Remains in DMR.			

2. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final BUA approval. VHSS completed and attached to protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
3. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of drug dosing requested.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer looking at PI's responses to questions.</p>			
4. # [REDACTED]	C	[REDACTED]	02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI Meeting and revision of protocol</p>			
6. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
7. # [REDACTED]	C	[REDACTED]	02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending additional discussion with IACUC subcommittee and further edits to the protocol.</p>			
9. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
10. # [REDACTED]	C	[REDACTED]	02-03-2022

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
12. #	C Y	n	02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	D		02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D		02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D		02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on euthanasia and humane endpoints.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	C Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Reviewer suggested wording modifications for procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
17. #	C	.	02-01-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	C Y		02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarifications of blood collection procedures.</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
19. # [REDACTED]	C	[REDACTED]	01-24-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed review and provided a new VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	D	[REDACTED]	01-25-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. SCRO, BIO and Chem safety reviews complete. Adverse effects clarified.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D	[REDACTED]	01-31-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal number justification and procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	C	[REDACTED]	02-01-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	D	[REDACTED]	01-27-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	C	[REDACTED]	02-01-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	C	[REDACTED]	02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
----------	----------	---------	---------------

1. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending review of PI responses.</p>			
2. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI providing additional regulation information.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	C	[REDACTED]	01-27-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	C	[REDACTED]	02-01-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D Y	[REDACTED]	01-27-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED] tment	02-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers and groups.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of potential effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final review of SOP.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			

10. # [REDACTED]	D Y	[REDACTED]	01-27-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	C	[REDACTED]	01-20-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
13. # [REDACTED]	C	[REDACTED]	01-20-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of potential effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D	[REDACTED]	02-01-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify number of animals and maximum timeframe.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending clarification about transportation details.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
18. # [REDACTED]	C	[REDACTED]	02-01-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
19. #	D Y		02-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
20. #	E		01-26-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification on drug dosages and potential adverse effects of agents.			
Additional discussion during the meeting included:			
a. None.			
21. #	D		01-26-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
22. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Pending anesthetic monitoring responses.			
Additional discussion during the meeting included:			
a. Remains in DMR.			
23. #	D		02-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
24. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. Pending PI.			
25. #	D		02-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification on specific volumes for drug compounds, pharmaceutical-grade and specifics on compounds.			
Additional discussion during the meeting included:			
a. None.			
26. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. Pending PI and location of space			
27. #	C		02-03-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
28. #	C		02-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
29. #	D		01-20-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 304 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	04-06-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
2. # [REDACTED]	D Y	[REDACTED]	02-03-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
3. # [REDACTED]	D	[REDACTED]	02-03-2022										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

4. #

C

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. pending Animal Leadership Committee decision.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

5. #

D

02-03-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarified number determination.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

6. #

D Y

02-03-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of procedures and medical grade skin glue.

Additional discussion during the meeting included:

a. Voted to approve.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

7. #

D

02-03-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. PI provided clarification regarding holding periods.

Additional discussion during the meeting included:

- a. Voted to approve.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

8. # [REDACTED]	D	[REDACTED]	02-03-2022
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

9. # [REDACTED]	C Y	[REDACTED]	02-03-2022
-----------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

10. # [REDACTED]	E	[REDACTED]	02-03-2022
------------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. No VHSS needed.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

11. # [REDACTED]	C Y	[REDACTED]	02-17-2022
------------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarify number of animals.

- b. Clarify temperature monitoring and normothermia maintenance.

Additional discussion during the meeting included:

- a. None.

<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 18 Withhold Approval 0 Abstain 0 Present 18 </div>			
12. #	D Y		02-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarify GMP product is used and is filter-sterilized. b. Terminology clarification c. Food intake and weigh monitoring procedure clarification. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. <div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 18 Withhold Approval 0 Abstain 1 Present 18 </div>			

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		02-13-2020	02-03-2022	02-13-2023
	C		02-11-2020	02-03-2022	02-11-2023
	C		02-06-2020	02-03-2022	02-06-2023
	C		02-06-2020	02-03-2022	02-06-2023
	D		02-05-2020	02-03-2022	02-05-2023
	D		02-06-2020	02-03-2022	02-06-2023
	D		02-06-2020	02-03-2022	02-06-2023
	C Y		02-06-2020	02-03-2022	02-06-2023
	C		02-12-2020	02-03-2022	02-12-2023
	D		02-06-2020	02-03-2022	02-06-2023
	C		02-06-2020	02-03-2022	02-06-2023
	C		02-12-2020	02-03-2022	02-12-2023
	D Y		02-13-2020	02-03-2022	02-13-2023
	D Y		02-06-2020	02-03-2022	02-06-2023

	C		02-13-2020	02-03-2022	02-13-2023
	C		02-06-2020	02-03-2022	02-06-2023
	C		02-06-2020	02-03-2022	02-06-2023
	D		02-06-2020	02-03-2022	02-06-2023
	D Y		02-07-2020	02-03-2022	02-07-2023
	D Y		02-06-2020	02-03-2022	02-06-2023
	D		02-12-2020	02-03-2022	02-12-2023
	D		02-18-2020	02-03-2022	02-18-2023
	D		02-06-2020	02-03-2022	02-06-2023
	C		02-18-2020	02-03-2022	02-18-2023
	D		02-06-2020	02-03-2022	02-06-2023
	C		02-18-2020	02-03-2022	02-18-2023
	D		02-06-2020	02-03-2022	02-06-2023
	D		02-11-2020	02-03-2022	02-11-2023
	D		02-18-2021	02-03-2022	02-18-2023
	C		02-16-2021	02-03-2022	02-16-2023
	C		02-18-2021	02-03-2022	02-18-2023
	D		02-18-2021	02-03-2022	02-18-2023
	D		02-18-2021	02-03-2022	02-18-2023
	D Y		02-17-2021	02-03-2022	02-17-2023
	C		02-18-2021	02-03-2022	02-18-2023
	D Y		02-18-2021	02-03-2022	02-18-2023
	C		02-05-2021	02-03-2022	02-05-2023
	C		02-09-2021	02-03-2022	02-09-2023
	D		02-18-2021	02-03-2022	02-18-2023
	D Y		02-18-2021	02-03-2022	02-18-2023

a. Voted to approve.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

2. #

D

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification and references requested regarding potential adverse effects of proposed procedure.

Additional discussion during the meeting included:

a. Pending PI responses.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

3. #

D Y

02-08-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. No chem hazard review confirmed though EH&S.

b. Clarification of proposed changes compared to procedures already approved.

c. C-section justification.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

4. #

D Y

02-03-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarify who will conduct the proposed screening.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

5. #

D

02-08-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Committee request modification to proposed study to include dose tolerance group.

Additional discussion during the meeting included:

a. Voted to send to DMR.

IACUC Vote	
------------	--

<table><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>			Approval	0	Withhold Approval	0	Abstain	0	Present	19		
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	19											
6. #	D	02-14-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:												
a. None.												
Additional discussion during the meeting included:												
a. Pending PI.												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	19											
7. #	D	02-03-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:												
a. None.												
Additional discussion during the meeting included:												
a. None.												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>			IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote												
Approval	19											
Withhold Approval	0											
Abstain	0											
Present	19											

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 01-18-2022	
2. 01-25-2022	
3. 01-31-2022	

Discussion:	1. Self reported deficiency due to staffing shortage and half of room needing to be delayed 1-2 days for cage changes.										
Action:	1. Complete facility inspection scheduled for the end of this month.										
<table> <tr><td colspan="2">IACUC Vote</td></tr> <tr><td>Approval</td><td>18</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>18</td></tr> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 01-13-2022	LAB	
2. 01-19-2022	LAB	
3. 01-19-2022	LAB	

4. 01-21-2022	LAB		
5. 01-24-2022	LAB		
6. 01-26-2022	LAB		
7. 01-27-2022	LAB		
8. 02-01-2022	LAB		

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. IACUC Policy-33 "Xenopus Oocyte Harvesting via Laparotomy"	
Discussion:	Discussed removal of anesthesia example.
Action:	Approved contingent on removal of anesthesia example.
2. IACUC Policy-25 "Animal Care and Use Occupational Health Program"	
Discussion:	Committee members requested additional time to review new exemption form.
Action:	Tabled.
3. IACUC Policy-32 "Rodent Genotyping and Identification Methods"	
Discussion:	Discussed "slow rollout" of the policy over the next year or so as protocols come up for annual renewal.
Action:	Approved contingent on slow rollout.
4. Steam whistle request	
Discussion:	Review of potential impact to any vivaria in process.
Action:	Pending results of sound studies.
5. 4th quarter fluid reports	
Discussion:	Communication error resulting in internal policy deviation.
Action:	To be addressed on facility inspection.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

February 17, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M111, M042, A095, M004, M092, A019, M119, M087, A109, M110, M226, M093, A013, M016, M024, M223, M001, M112, M114

Excused:

M222, M102, M090

Guests:

M224, M116, A017

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the December 16, 2021, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1. #	Category: D										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul style="list-style-type: none">a. Follow up questions entered on potential adverse effects of procedure.b. relevant information requested from CVS on murine thoracic anatomy. Additional discussion during the meeting included: <ul style="list-style-type: none">a. pending PI response to follow up questions. Committee concerned about possibility of unidentified hypoxemia.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>14</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	14
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	14										

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

	Action: Euthanasia following neuropathic injuries sustained during a relocation procedure.
	Action: Inadvertent second vasectomy initiated.
	PCRM action
	Action: PCRM filed allegations and complaint to USDA against UCD and Neuralink.
	completed
	Action: Anonymous concern of improper procedures; no evidence to support claim.
	Action: Fish standpipe, PAM, amendment in review.
	Action: Amendment in process. PAM TBD.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	C		02-14-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
2. #	C		02-10-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. BUA approved by biosafety. Additional discussion during the meeting included: a. None.			
3. #	C		02-10-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. BUA approved by biosafety. Additional discussion during the meeting included: a. None.			
4. #	C		02-17-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.			
5. #	D		-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
6. #	D		02-10-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on BUA, VHSS, and policies referenced.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI and reviewers</p>			
8. #	C		02-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	D		02-07-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers and source.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	C		02-08-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. IACUC requesting notification of device placement so CVS can observe.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
12. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending decision form Animal Leadership Team.</p>			
13. #	C		-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
14. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
15. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending reviewer.</p>			
16. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of species.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending review of PI responses.</p>			
17. #	C Y		02-16-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding euthanasia procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	C		02-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	C		02-11-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on secondary method of euthanasia after anesthesia.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		02-15-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C Y		02-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Numbers clarification.</p> <p>b. Clarify body temperature monitoring and normothermia maintenance.</p>			

Additional discussion during the meeting included: a. None.			
22. #	D		02-08-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on drugs listed and toxicities. Additional discussion during the meeting included: a. None.			
23. #	D		02-14-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
24. #	C Y		02-16-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
25. #	C		02-17-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
26. #	D Y		02-16-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		02-17-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of adverse effects and monitoring. Additional discussion during the meeting included: a. None.			
2. #	D		02-16-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Confirmed with TRACS request for cage can be accommodated. Additional discussion during the meeting included: a. None.			

3. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI providing additional regulation information.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
4. # [REDACTED]	D	[REDACTED]	02-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	C	[REDACTED]	02-15-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Updated alt contact qualifications statement.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
7. # [REDACTED]	D Y	[REDACTED]	02-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of potential FSH and LH side effects, if any.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	C	[REDACTED]	02-16-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D Y	[REDACTED]	02-07-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Husbandry SOP updated and attached.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D Y	[REDACTED]	02-07-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D	[REDACTED]	02-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

12. # [REDACTED]	D	[REDACTED]	02-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Updated VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	D Y	[REDACTED]	02-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of potential FSH and LH side effects, if any.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D Y	[REDACTED]	02-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending additional information from PI on max number and duration.</p> <p>Additional discussion during the meeting included:</p> <p>a. Continue in DMR.</p>			
16. # [REDACTED]	D Y	[REDACTED]	02-08-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on amendment purpose.</p> <p>b. C-section justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D	[REDACTED]	02-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D Y	[REDACTED]	02-07-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Transportation details and rooms clarified.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	02-15-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	C	[REDACTED]	-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
21. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
22. #	D		02-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	D		02-14-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		02-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D		02-16-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D		02-08-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. A dose-response study has been added as recommended by IACUC.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending clarification on anesthesia technique.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
28. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Questions entered regarding the difference between a feed/manger gate and a chute.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI.</p>			

29. # [REDACTED]	D	[REDACTED]	02-08-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. # [REDACTED]	D	[REDACTED]	02-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures and animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. # [REDACTED]	C	[REDACTED]	02-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. # [REDACTED]	D	[REDACTED]	02-11-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. # [REDACTED]	D	[REDACTED]	02-14-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
34. # [REDACTED]	D	[REDACTED]	02-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified dose determination.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
35. # [REDACTED]	C Y	[REDACTED]	02-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Approval of animals returning to the colony: Center decision.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 200 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date
----------	----------	-------	------

1. #	D		Approved 03-03-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on volume of tumor burden. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
2. #	D		02-17-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
3. #	C		02-22-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification requested regarding animal numbers and monitoring during anesthesia. Committee was comfortable with PI's expertise, trainings, and proposed training record documentation of staff of euthanasia methods. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
4. #	D Y		02-17-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												

5. # [REDACTED]	D	[REDACTED]	02-17-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Numbers clarification and specification of non-pharmaceutical grade substances.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
6. # [REDACTED]	E	[REDACTED]	02-17-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of monitoring and endpoints.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	1	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	1												
Present	20												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	D	[REDACTED]	02-20-2020	02-17-2022	02-20-2023
[REDACTED]		[REDACTED]	02-20-2020	02-17-2022	02-20-2023
[REDACTED]	D	[REDACTED]	02-25-2020	02-17-2022	02-25-2023
[REDACTED]	C Y	[REDACTED]	02-05-2020	02-17-2022	02-05-2023
[REDACTED]	D	[REDACTED]	02-25-2020	02-17-2022	02-25-2023
[REDACTED]	C	[REDACTED]	02-28-2020	02-17-2022	02-28-2023
[REDACTED]	D Y	[REDACTED]	02-20-2020	02-17-2022	02-20-2023
[REDACTED]	E Y	[REDACTED]	02-20-2020	02-17-2022	02-20-2023
[REDACTED]	D Y	[REDACTED]	03-04-2020	02-17-2022	03-04-2023
[REDACTED]	D	[REDACTED]	03-04-2020	02-17-2022	03-04-2023
[REDACTED]	D Y	[REDACTED]	03-04-2020	02-17-2022	03-04-2023

	D Y		02-21-2020	02-17-2022	02-21-2023
	C		03-03-2020	02-17-2022	03-03-2023
	D		03-02-2020	02-17-2022	03-02-2023
	C		02-19-2020	02-17-2022	02-19-2023
	C		02-20-2020	02-17-2022	02-20-2023
	C		02-19-2020	02-17-2022	02-19-2023
	C		02-24-2020	02-17-2022	02-24-2023
	C		03-04-2020	02-17-2022	03-04-2023
	C Y		02-20-2020	02-17-2022	02-20-2023
	C		03-04-2020	02-17-2022	03-04-2023
	C		03-04-2020	02-17-2022	03-04-2023
	D Y		02-23-2021	02-17-2022	02-23-2023
	E		02-22-2021	02-17-2022	02-22-2023
	C		02-18-2021	02-17-2022	02-18-2023
	C Y		03-04-2021	02-17-2022	03-04-2023
	D Y		03-04-2021	02-17-2022	03-04-2023
	D		02-24-2021	02-17-2022	02-24-2023
	B Y		02-22-2021	02-17-2022	02-22-2023
	C		03-04-2021	02-17-2022	03-04-2023
	C		03-04-2021	02-17-2022	03-04-2023
	D		03-04-2021	02-17-2022	03-04-2023
	D Y		03-04-2021	02-17-2022	03-04-2023
	D		03-04-2021	02-17-2022	03-04-2023
	D		03-02-2021	02-17-2022	03-02-2023
	C		03-01-2021	02-17-2022	03-01-2023

	D Y		02-24-2021	02-17-2022	02-24-2023
	C		02-25-2021	02-17-2022	02-25-2023
	D Y		03-04-2021	02-17-2022	03-04-2023
	C		03-04-2021	02-17-2022	03-04-2023

Discussion:	<p>██████████ one staff member is on the last step of the OHSS renewal process and just needs to complete their in person appt.</p> <p>██████████ sent PI and alt. contact updated genotyping policy and provided details of changes to ensure they remain in compliance.</p> <p>██████████ -permit information is expired. PI verified no animals have been worked with since expiration date. A new permit will only be obtained if more studies are needed in the future.</p> <p>██████████ amendment submitted to clarify use of non-pharm grade drug used in clinical trial.</p> <p>██████████ - section 9 actually food scheduling per and incorrect policy referenced in procedures section.</p>										
Action Items:	<p>██████████ committee approved the annual renewals.</p> <p>██████████ committee approved adding a statement in the original protocol that PI has been notified of policy changes.</p> <p>██████████ committee approved the annual renewal.</p> <p>██████████ committee approved the annual renewal.</p> <p>██████████ - committee approved the annual renewal and updating section 9 and 14a of the original protocol.</p>										
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	02-17-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

2. #	C		02-17-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
3. #	D		02-17-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PAM also discussed during meeting. Proposed plan to have CVS provide training in future when technique is needed again is approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p>													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
4. #	D		02-17-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed phenotype adverse effect and approved BCS system in lieu of just basing humane endpoint on weight loss.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p>													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
5. #	D Y		03-03-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Housing clarification.</p> <p>b. Disposition.</p> <p>c. Clarify need for surgery.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												

XII. Animal Housing/Facility Inspections:

Inspection	Vivarium
------------	----------

Date	
1. 01-13-2022	
2. 01-24-2022	

Discussion:	2. Although caging was sent to the cage washer, the accessories were hand-washed and no QA was performed.										
Action:	2. PI's staff will ensure all caging and accessories are cleaned in the cage washer.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 01-10-2022	LAB	
2. 02-07-2022	LAB	
3. 02-10-2022	LAB	
4. 02-14-2022	LAB	
5. 01-21-2022	PAM	
6. 01-27-2022	PAM	
7. 02-14-2022	PAM	

Discussion:	6. Animals were BAR, incision intact, normal eating and drinking. No animal welfare issues noted. They received 48 hours coverage of analgesia.										
Action:	6. PI has submitted an amendment to clarify which drugs will be given to all animals and which drugs will be given as needed. It will be reviewed at the next committee meeting.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1.	
Discussion:	Assessment following surgery. Opioid or local anesthetic based on results observed.
Action:	Subcommittee of Chair, Vice Chair and AV to define and convey expectations to PI.
Change in SIC and TIC for Equestrian Center	
Discussion:	Retirement.

Action:	Approved.
IACUC Policy-25 "Animal Care and Use Occupational Health Program" and attachments 1-6	
Discussion:	None.
Action:	Approved.
IACUC Policy-36 "Adoption of Animals Used in Research and Teaching"	
Discussion:	None.
Action:	Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

**University of California, Davis
IACUC Business Administration System**

**March 03, 2022
Meeting Minutes**

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:**Present:**

M009, M222, M111, A095, M004, M092, A019, M119, M087, A109, M110, M226, M093, A013, M016, M024, M223, M001, M112, M114

Excused:

M097, M102, M090, M042

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1. #		Category: D										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:												
a. reviewer's concern over possible adverse effects of procedures.												
Additional discussion during the meeting included:												
a. Tabled pending investigator's response.												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	19											

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
CABA
Action: Raccoon activity.
Action: PAM personnel.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	D		-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI.</p>			
2. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI and review/rewrite</p>			
3. #	D		03-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on tumor size should be included and criteria for maximum growth before euthanasia.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending MOUs from PI.</p>			
5. #	C		03-01-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of personnel, inclusion/exclusion criteria, and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #	C		02-28-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of anesthesia administration.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	C		03-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of restraint methods</p> <p>Clarification of potential adverse effects</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	C		02-28-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarification of other species.</p>			
9. #	C		-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
10. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
11. # [REDACTED]	C	[REDACTED]	02-22-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding monitoring of animals and training records.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	02-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C	[REDACTED]	03-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED]	03-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA amendment approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI providing additional regulation information.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
2. # [REDACTED]	D	[REDACTED]	02-26-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on MOU, consent and criteria for the privately owned animals.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. #	C Y		03-01-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	C		03-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. #	C		02-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on if the elephants are domestic.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #	D		03-01-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer</p>			
8. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending additional information from PI on max number and duration.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	E		03-01-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	D Y		03-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
11. #	C		03-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
12. #	C		03-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
13. #	D		03-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
14. #	D		03-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
15. #	D Y		02-17-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
16. #	D Y		03-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
17. #	C		02-23-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification on blood withdrawal and procedure.			
Additional discussion during the meeting included:			
a. None.			
18. #	C		02-28-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification of NPG drug.			
Additional discussion during the meeting included:			
a. None.			
19. #	D Y		03-03-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Housing clarification. b. Disposition. c. Clarify need for surgery. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
20. # [REDACTED]	C	[REDACTED]	02-22-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
21. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending PI's responses. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
22. # [REDACTED]	D	[REDACTED]	03-02-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
23. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Amendments to BUA pending. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending BIO. 			
24. # [REDACTED]	C	[REDACTED]	03-02-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
25. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI. 			

VIII. Administrative and Veterinary Verification Amendments:

Total of 229 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	05-31-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI. Voted to send to DR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
2. # [REDACTED]	D Y	[REDACTED]	03-03-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
3. # [REDACTED]	D	[REDACTED]	03-17-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Additional drug dosage timing recommendations.</p> <p>b. Additional clarification on bead administration.</p> <p>c. Additional blood collection details requested.</p> <p>d. Incision size recommendation.</p> <p>e. Additional clarifications regarding potential adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
4. # [REDACTED]	C	[REDACTED]	03-03-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Contacted collaborator in the Mammalian Society regarding re-use of pit tag needles. Common practice includes maximum number of uses and cleaning in between each use.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p>													

<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
5. # [REDACTED]	D Y	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Reviewers have concerns regarding acclimation period, length of anesthesia, and potentially model requested.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee requesting tabling the protocol for review of responses at next meeting.</p> <div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 20 </div>			
6. # [REDACTED]	D	[REDACTED]	03-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Replacement protocol. Chemical safety completed review and verified VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
7. # [REDACTED]	E	[REDACTED]	03-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 19 Withhold Approval 0 Abstain 0 Present 19 </div>			

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	C	[REDACTED]	03-05-2020	03-03-2022	03-05-2023
[REDACTED]	D Y	[REDACTED]	03-09-2020	03-03-2022	03-09-2023

	B		03-13-2020	03-03-2022	03-13-2023
	C		03-05-2020	03-03-2022	03-05-2023
	D		03-05-2020	03-03-2022	03-05-2023
	D		03-10-2020	03-03-2022	03-10-2023
	D		03-06-2020	03-03-2022	03-06-2023
	D		03-05-2020	03-03-2022	03-05-2023
	C		03-05-2020	03-03-2022	03-05-2023
	C		03-05-2020	03-03-2022	03-05-2023
	D		03-18-2020	03-03-2022	03-18-2023
	C		03-15-2021	03-03-2022	03-15-2023
	D Y		03-08-2021	03-03-2022	03-08-2023
	D		03-18-2021	03-03-2022	03-18-2023
	D		03-18-2021	03-03-2022	03-18-2023
	C		03-17-2021	03-03-2022	03-17-2023
	C		03-17-2021	03-03-2022	03-17-2023
	C		03-18-2021	03-03-2022	03-18-2023
	C		03-09-2021	03-03-2022	03-09-2023
	C		03-17-2021	03-03-2022	03-17-2023
	C		03-17-2021	03-03-2022	03-17-2023
	D		03-18-2021	03-03-2022	03-18-2023
	D		03-18-2021	03-03-2022	03-18-2023
	C Y		03-18-2021	03-03-2022	03-18-2023
	D		03-18-2021	03-03-2022	03-18-2023
	D		03-18-2021	03-03-2022	03-18-2023
	D		03-18-2021	03-03-2022	03-18-2023

	D		03-17-2021	03-03-2022	03-17-2023
	C		03-18-2021	03-03-2022	03-18-2023
	C Y		03-15-2021	03-03-2022	03-15-2023
	D		03-18-2021	03-03-2022	03-18-2023
	D		03-18-2021	03-03-2022	03-18-2023
	D Y		03-18-2021	03-03-2022	03-18-2023

Discussion:	<p>██████████ - one staff member is on the last process of the OHSS process requiring an in person appointment.</p> <p>██████████ alternate contact's ACU 101 is expired.</p> <p>██████████ permit information on protocol is showing as expired. PI provided updated federal permit and state permit is still pending CDFW.</p> <p>██████████ and ██████████ sent PI updated genotyping policy and recommended amendments for anesthesia and analgesia as needed.</p>										
Action Items:	<p>██████████ - committee approved the annual renewals.</p> <p>██████████ moved to the next agenda.</p> <p>██████████ committee approved renewal and up date to protocol.</p> <p>██████████ and ██████████ committee approved renewals and making a notation in the protocol regarding updated policy.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>20</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	20										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	C Y	[REDACTED]	03-03-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Discussed future use of the animal in teaching labs.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D Y	[REDACTED]	03-03-2022										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

3. # [REDACTED]	D Y	[REDACTED]	03-03-2022
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

4. # [REDACTED]	D	[REDACTED]	03-03-2022
-----------------	---	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification requested regarding contacting CVS.

Additional discussion during the meeting included:

a. Committee voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

5. # [REDACTED]	C	[REDACTED]	03-03-2022
-----------------	---	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

6. # [REDACTED]	C Y	[REDACTED]	03-03-2022
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Potential adverse effects.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
------------	--

<table><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				Approval	19	Withhold Approval	0	Abstain	0	Present	19		
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
7. #	D Y		03-03-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
8. #	D		03-03-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
9. #	D		03-07-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Discussed USDA category.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
10. #	E		05-12-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Request for PI to provide further justification regarding post-op medication use. Additional discussion during the meeting included: a. Committee voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0		
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												

	Present	20											
11. #	D Y		03-03-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Additional criteria to determine when drugs will be given. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
12. #	D		03-03-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
13. #	D		03-03-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification provided as to when certain medications would be used based on outcomes and CVS input. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 01-25-2022	
2. 01-27-2022	

Discussion:	1. Common facility issues due to normal wear and tear. 2. Mostly common facility issues due to normal wear and tear. Last deficiency is being worked to ensure all vaporizers have been calibrated based on manufacturers guidelines.
Action:	1. Work orders have already been placed for repairs. 2. Work orders have already been placed for repairs. staff working with vendor and CVS to remedy yearly calibration recommendations from manufacturer.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 11-30-2021	LAB	
2. 02-23-2022	LAB	
3. 02-28-2022	PAM	

Discussion:	None.										
Action:	None.										
<table> <tr> <td colspan="2">IACUC Vote</td></tr> <tr> <td>Approval</td><td>18</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>18</td></tr> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:				
Inspection Date	Agency	Location	Summary	Discussion
1. 03-01-2022	USDA	Site 2	Focused inspection 3/1/22 in response to PCRM complaint "No non-compliant items".	FYI.

XV. Other Discussion Items:

Topic
AAALAC site visit dates confirmed: November 9 and week of November 14, 2022
Discussion: FYI.
Action: None.
IACUC Policy-17 "Use of Radios and Other Sound Generating Devices in the Vivaria"
Discussion: None.
Action: Approved.
IACUC Policy-44 "Use of Non-Pharmaceutical Grade Sodium Pentobarbital for Anesthesia of Laboratory Animals"
Discussion: None.
Action: Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

March 17, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M097, M222, M102, M111, M090, A095, M004, M092, A019, M119, A109, M110, M226, M093, A013, M024, M223, M001

Excused:

M009, M042, M087, M016, M112, M114

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

1. # [REDACTED]	Category: D Y										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Responses are still pending from the PI. Additional discussion during the meeting included: a. Tabled.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	18										

III. Amendments Tabled From Previous Meetings:

1. # [REDACTED]	Category: D										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. pending PI response to follow up questions on potential adverse effects.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	18										

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

Action: PAM and amendment.

Chemical Hygiene review

Action: Notification of first responder report however no event details provided to IACUC Office. Chemical Safety Officer reviewing protocol and VHSS notifications processes, training and responsibilities with IACUC Office. IACUC Office internal procedure processes reviewed with IACUC staff and AV.

Action: 3/14/22 (date correction) Facility manager notified IACUC Office of one unaccounted mouse. Live trap placed in room however suspect accounting error. IACUC staff following up with PI and Facility Manager.

Meyer Hall 21974, 21349, 22646, 21604 Temperature Fluctuation

Action: No animal welfare issues.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
2. # [REDACTED]	D	[REDACTED]	03-10-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. All changes accepted</p>			
3. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
4. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			

5. # [REDACTED]	C	[REDACTED]	03-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D	[REDACTED]	03-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
8. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
9. # [REDACTED]	C	[REDACTED]	03-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
11. # [REDACTED]	D	[REDACTED]	03-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	03-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed environmental impact of the turtles.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

13. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
14. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending clarification of disposition of milk</p>			
15. # [REDACTED]	D	[REDACTED]	03-15-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Updated adverse effects and hazardous materials sections.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	03-15-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	03-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified level of interaction with enrichment.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	03-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Specified number of animals used at one time.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	C	[REDACTED]	03-16-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	C	[REDACTED]	03-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI providing additional regulation information.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	C	[REDACTED]	03-11-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	C	[REDACTED]	03-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	C	[REDACTED]	03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D Y	[REDACTED]	03-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI provided clarification regarding anesthesia regime.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D Y	[REDACTED]	03-14-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D	[REDACTED]	03-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding intent of amendment and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

9. # [REDACTED]	D Y	[REDACTED]	03-15-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. The PI acknowledged they should dispose of any excess as hazardous waste due to it's aquatic toxicity per the chemical safety officer.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending additional information from PI on max number and duration.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	E	[REDACTED]	03-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	D Y	[REDACTED]	03-16-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	Y	[REDACTED]	03-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED]	03-04-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
16. # [REDACTED]	D Y	[REDACTED]	03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Bio and chem safety confirmed there is no hazard present in changing the two drugs. PI clarified imaging procedures and Bio confirmed BUA covered these studies.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	03-17-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarification of safety precautions and public interaction with animals</p>			
18. #	E		03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D		03-11-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D Y		03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D		03-07-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified adverse effects duration and category.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	C		03-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		03-16-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA Amended.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
26. #	C Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	D		03-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI provided clarification regarding number of animals being tattooed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	C Y		03-16-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	D Y		03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	C Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
31. #	D		03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	C		03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. #	E		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final review.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
34. #	E		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's response to questions regarding analgesia.</p> <p>Additional discussion during the meeting included:</p>			

a. Remains in DMR.			
35. # [REDACTED]	D	[REDACTED]	03-17-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
36. # [REDACTED]	C Y	[REDACTED]	03-04-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
37. # [REDACTED]	C Y	[REDACTED]	03-04-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
38. # [REDACTED]	C Y	[REDACTED]	03-16-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
39. # [REDACTED]	C	[REDACTED]	03-14-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 215 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	03-17-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification of permit requirements.
- b. Clarification of potential adverse effects and how they will be addressed.
- c. Corrected a typo.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	18

<table><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				Withhold Approval	0	Abstain	0	Present	18				
Withhold Approval	0												
Abstain	0												
Present	18												
2. #	D		03-17-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Clarification of ventilation procedures.b. clarification of catheter placement procedure.c. Clarification of opioid reversal and post-op pain meds.d. Corrected a typo. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
3. #	D Y		06-09-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Clarification of acronyms.b. Request for text to be edited further to ensure information is in correct protocols sections without being unnecessarily duplicated.c. Ensure all drugs listed in section 14a are in 14b table. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
4. #	D		03-17-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Clarified adverse effects duration and category. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
5. #	D		03-17-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Fixed typos. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table><tr><th colspan="2">IACUC Vote</th></tr></table>				IACUC Vote									
IACUC Vote													

<table border="1"> <tr><td>Approval</td><td>19</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>19</td></tr> </table>				Approval	19	Withhold Approval	0	Abstain	0	Present	19		
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
6. #	C Y		03-17-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr><td colspan="2">IACUC Vote</td></tr> <tr><td>Approval</td><td>19</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>19</td></tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
7. #	C Y		03-17-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr><td colspan="2">IACUC Vote</td></tr> <tr><td>Approval</td><td>19</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>19</td></tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		03-05-2020	03-17-2022	03-05-2023
	C		03-05-2020	03-17-2022	03-05-2023
	D		03-19-2020	03-17-2022	03-19-2023
	C		03-19-2020	03-17-2022	03-19-2023
	D		03-19-2020	03-17-2022	03-19-2023
	D		04-01-2020	03-17-2022	04-01-2023
	D Y		03-19-2020	03-17-2022	03-19-2023
	D		03-24-2020	03-17-2022	03-24-2023
	D Y		03-19-2020	03-17-2022	03-19-2023
	C		03-19-2020	03-17-2022	03-19-2023

	D		03-19-2020	03-17-2022	03-19-2023
	D Y		03-19-2020	03-17-2022	03-19-2023
	D		03-19-2020	03-17-2022	03-19-2023
	D		03-19-2020	03-17-2022	03-19-2023
	D Y		03-19-2020	03-17-2022	03-19-2023
	C		03-19-2020	03-17-2022	03-19-2023
	C		03-21-2020	03-17-2022	03-21-2023
	D		03-24-2020	03-17-2022	03-24-2023
	C		03-31-2020	03-17-2022	03-31-2023
	D		04-01-2020	03-17-2022	04-01-2023
	E		03-23-2020	03-17-2022	03-23-2023
	C		03-20-2020	03-17-2022	03-20-2023
	C		03-26-2020	03-17-2022	03-26-2023
	C		03-26-2020	03-17-2022	03-26-2023
	C Y		04-01-2021	03-17-2022	04-01-2023
	B		03-25-2021	03-17-2022	03-25-2023
	C		03-23-2021	03-17-2022	03-23-2023
	B		04-01-2021	03-17-2022	04-01-2023
	C		03-29-2021	03-17-2022	03-29-2023
	D		03-23-2021	03-17-2022	03-23-2023
	D		03-30-2021	03-17-2022	03-30-2023
	E		04-01-2021	03-17-2022	04-01-2023
	D		04-01-2021	03-17-2022	04-01-2023
	D		04-01-2021	03-17-2022	04-01-2023
	C		04-01-2021	03-17-2022	04-01-2023
	D Y		04-01-2021	03-17-2022	04-01-2023
	D		04-01-2021	03-17-2022	04-01-2023

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed PAM which led to PI submitting an amendment to comply with the updated genotyping policy.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee approved the amendment.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
2. #	C		03-17-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Information requested regarding to expected response to euthanasia methods.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
3. #	C		03-17-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Discussed certification for physical methods</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>18</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>1</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	1	Present	19
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	1												
Present	19												
4. #	D Y		03-24-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on locations for imaging, procedures and inoculations.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>18</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
5. #	D		04-14-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed adverse effects and plans to work with CVS once path results are finalized. PI to hold off ordering any more animals until after a plan is formulated with CVS and presented to the IACUC.</p> <p>Additional discussion during the meeting included:</p>													

a. Tabled.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

6. #

D Y

03-17-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. PI provided clarification regarding procedure details.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

7. #

D

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. May not need an amendment. Requested DR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	17

8. #

D

03-17-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

9. #

D

03-17-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of contradictory wording regarding monitoring.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

10. #

D

03-17-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Additional clarification on monitoring.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

11. # [REDACTED]	D Y [REDACTED]	03-17-2022
------------------	----------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Committee voted to approve.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

12. # [REDACTED]	D Y [REDACTED]	03-17-2022
------------------	----------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

13. # [REDACTED]	D Y [REDACTED]	03-17-2022
------------------	----------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

14. # [REDACTED]	D Y [REDACTED]	03-17-2022
------------------	----------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Committee voted to approve.

IACUC Vote	
------------	--

Approval	17
Withhold Approval	0
Abstain	0
Present	17

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 03-08-2022	

Discussion:	1 & 2 - Moved to the next agenda.										
Action:	1 & 2 - Tabled.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>17</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </tbody> </table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 10-12-2021	LAB	
2. 02-28-2022	LAB	
3. 02-28-2022	LAB	
4. 03-02-2022	LAB	
5. 03-16-2022	LAB	
6. 03-16-2022	LAB	
7. 01-21-2022	PAM	
8. 02-10-2022	PAM	
9. 02-24-2022	PAM	
10. 03-02-2022	PAM	

Discussion:	None.
Action:	None.

XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:				
Inspection Date	Agency	Location	Summary	Discussion
1. 03-01-2022	USDA	Site 2: Focused	Focused inspection on 3/1, 3/2 and 3/4 in response to PCRM complaint. "No non-compliant items."	
2. 03-16-2022	USDA	Site 2: Routine	Routine inspection 3/16, 3/17. Findings TBD	

3. 03-16-2022	USDA	Site 1: Focused	Focused inspection 3/16, 3/17. Findings TBD	
------------------	------	-----------------	---	--

XV. Other Discussion Items:

Topic	
	PI Maintained Sheep
Discussion: None.	
Action: Approved.	
GBSF Refrigerator	
Discussion: AV will send letter to users reminding users refrigerator availability, intent and correct usage.	
Action: None.	
IACUC Policy-46 "Social Housing of Social Species"	
Discussion: Added other male intact livestock to default exclusions.	
Action: Approved.	
LAGO Imager SOP	
Discussion: None.	
Action: Approved.	

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

March 31, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M222, M102, M111, M042, A095, M004, M092, A019, M087, A109, M110, M226, M093, A013, M016, M024, M223, M001, M112, M114

Excused:

M090, M119

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the January 6, 2022, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

The IACUC reviewed and approved the January 6, 2022, meeting minutes as written.

IACUC Vote	
Approval	22
Withhold Approval	0
Abstain	0
Present	22

The IACUC reviewed and approved the January 20, 2022, meeting minutes as written.

IACUC Vote	
Approval	22
Withhold Approval	0
Abstain	0
Present	22

The IACUC reviewed and approved the February 3, 2022, meeting minutes as written.

IACUC Vote	
Approval	22
Withhold Approval	0
Abstain	0
Present	22

II. Protocols Tabled From Previous Meetings:

1. #		Category: D Y										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p style="margin-left: 40px;">a. Pending PI's responses to question posed at previous meeting.</p> <p>Additional discussion during the meeting included:</p> <p style="margin-left: 40px;">a. Tabled.</p>												
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Approval</td> <td style="text-align: right; padding: 2px;">0</td> </tr> <tr> <td style="padding: 2px;">Withhold Approval</td> <td style="text-align: right; padding: 2px;">0</td> </tr> <tr> <td style="padding: 2px;">Abstain</td> <td style="text-align: right; padding: 2px;">0</td> </tr> <tr> <td style="padding: 2px;">Present</td> <td style="text-align: right; padding: 2px;">22</td> </tr> </tbody> </table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	22											

III. Amendments Tabled From Previous Meetings:

1. #		Category: D										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p style="margin-left: 40px;">a. Pending pathology results. Committee requested area CVS veterinarian to attend the next meeting to discuss proposed plan moving forward.</p> <p>Additional discussion during the meeting included:</p> <p style="margin-left: 40px;">a. Tabled.</p>												
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Approval</td> <td style="text-align: right; padding: 2px;">0</td> </tr> <tr> <td style="padding: 2px;">Withhold Approval</td> <td style="text-align: right; padding: 2px;">0</td> </tr> <tr> <td style="padding: 2px;">Abstain</td> <td style="text-align: right; padding: 2px;">0</td> </tr> <tr> <td style="padding: 2px;">Present</td> <td style="text-align: right; padding: 2px;">22</td> </tr> </tbody> </table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	22											

IV. Reports of Concern, Events and Incidents:

<p>The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:</p>
<div style="background-color: black; width: 100px; height: 15px; margin-bottom: 5px;"></div> <div style="background-color: black; width: 100px; height: 15px; margin-bottom: 5px;"></div> <p style="margin-left: 20px;">Action: IACUC staff looking into concern and starting investigation process.</p>
<p>Re-training [REDACTED] - PI provided re-training to the lab regarding documentation of movement of animals and updated room logs for clearer tracking.</p>
<p style="margin-left: 20px;">Action: Discussed PAM during inspection section of agenda. Committee agreed of PI's training plan.</p>
<div style="background-color: black; width: 100px; height: 15px; margin-bottom: 5px;"></div> <div style="background-color: black; width: 100px; height: 15px; margin-bottom: 5px;"></div> <p style="margin-left: 20px;">Action: Dehiscence records, retraining.</p>

V. Veterinary Care Program Updates:

<p>The Attending Veterinarian provided the following updates to the committee:</p>
<p style="margin-left: 40px;">None at this time.</p>

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending MOUs from PI.</p>			
2. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers, drugs, procedures, and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
3. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
4. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
5. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
6. # [REDACTED]	C	[REDACTED]	03-21-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of acronyms.</p> <p>b. Request for text to be edited further to ensure information is in correct protocols sections without being unnecessarily duplicated.</p> <p>c. Ensure all drugs listed in section 14a are in 14b table.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	C	[REDACTED]	03-31-2022

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of animal numbers justification and group size. b. Update course instructor information <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
9. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI. 			
10. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Clarified numbers 			
11. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI responses. 			
12. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI 			
13. # [REDACTED]	C	[REDACTED]	03-28-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification on personnel duties. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
14. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI 			
15. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI 			

16. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI providing additional regulation information.</p> <p>Additional discussion during the meeting included:</p> <p>a. Continue in DMR.</p>			
2. # [REDACTED]	C	[REDACTED]	03-30-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	03-21-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on the procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	Y	[REDACTED]	03-31-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. requested that waiver be attached.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D Y	[REDACTED]	03-29-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	C	[REDACTED]	03-30-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed amendment vs new protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D Y	[REDACTED]	03-31-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

8. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending additional information from PI on max number and duration.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remain in DMR.</p>			
9. # [REDACTED]	C	[REDACTED]	03-30-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Added detail on monitoring eyes.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D Y	[REDACTED]	03-30-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Remove unnecessary questions from text fields.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	C	[REDACTED]	03-30-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	D	[REDACTED]	03-29-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C	[REDACTED]	03-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D Y	[REDACTED]	03-24-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on location and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D	[REDACTED]	03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	03-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

17. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending amended BUA. Clarified wording.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	C Y	[REDACTED]	03-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	03-31-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Added detail on anesthesia and euthanasia.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	C Y	[REDACTED]	03-31-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
22. # [REDACTED]	E	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's responses from previous meeting.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
23. # [REDACTED]	E	[REDACTED]	03-30-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	D Y	[REDACTED]	03-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	D	[REDACTED]	03-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
26. #	C		03-31-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
27. #	C		03-31-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
28. #	D		03-30-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 162 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	05-24-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Questions on procedures, drugs, and BUA. Additional discussion during the meeting included: a. Voted to be Tabled.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
2. # [REDACTED]	D Y	[REDACTED]	03-31-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0				
IACUC Vote													
Approval	19												
Withhold Approval	0												

		<table><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>20</td></tr></table>	Abstain	1	Present	20							
Abstain	1												
Present	20												
3. #	C		03-31-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
4. #	D		04-14-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI. Additional discussion during the meeting included: a. Voted to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
5. #	D		04-12-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI. Additional discussion during the meeting included: a. Voted to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
6. #	C Y		03-31-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified housing while singly housed and tests completed prior to adoption. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0		
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												

	Present	22											
7. #	C		03-31-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Added VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												
Present	22												
8. #	C Y		04-04-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed USDA covered areas. MOU needed to proceed with other species.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		04-02-2020	03-31-2022	04-02-2023
	D Y		04-02-2020	03-31-2022	04-02-2023
	C		04-02-2020	03-31-2022	04-02-2023
	C		04-02-2020	03-31-2022	04-02-2023
	D		04-07-2020	03-31-2022	04-07-2023
	C Y		04-02-2020	03-31-2022	04-02-2023
	D		04-02-2020	03-31-2022	04-02-2023
	C		04-02-2020	03-31-2022	04-02-2023
	B		04-15-2020	03-31-2022	04-15-2023
	D Y		04-02-2020	03-31-2022	04-02-2023
	D		04-03-2020	03-31-2022	04-03-2023

	C		4-15-2020	03-31-2022	04-15-2023
	D Y		4-14-2021	03-31-2022	04-14-2023
	D Y		3-30-2021	03-31-2022	03-30-2023
	C		3-10-2021	03-31-2022	03-10-2023
	C		3-29-2021	03-31-2022	03-29-2023
	D		4-13-2021	03-31-2022	04-13-2023
	C		4-13-2021	03-31-2022	04-13-2023
	C		4-13-2021	03-31-2022	04-13-2023
	C Y		4-15-2021	03-31-2022	04-15-2023
			4-15-2021	03-31-2022	04-15-2023
	C		4-15-2021	03-31-2022	04-15-2023
	C		4-13-2021	03-31-2022	04-13-2023
	C		4-14-2021	03-31-2022	04-14-2023
	D		4-01-2021	03-31-2022	04-01-2023
	C		4-15-2021	03-31-2022	04-15-2023
	C		4-13-2021	03-31-2022	04-13-2023
	D Y		4-03-2021	03-31-2022	04-03-2023
	D		4-15-2021	03-31-2022	04-15-2023
	C		4-15-2021	03-31-2022	04-15-2023
	D		4-15-2021	03-31-2022	04-15-2023
	D		4-15-2021	03-31-2022	04-15-2023

Discussion: [REDACTED] - IACUC staff working with PI to include transportation details. An amendment will be submitted.

[REDACTED] & [REDACTED] - permits on protocol have expired. PI's confirmed they are in review and will send to IACUC office once received.

[REDACTED] and [REDACTED] one staff member is in the renewal OHSS process. On last step of in person appointment.

[REDACTED] Other veterinarian listed in section 11. AV working on MOU.

[REDACTED] Discussed section 8 for CT protocols. No VHSS required.

Information should be included in consent form. Section 8 checked should be checked lab only.

[REDACTED] & [REDACTED] - PI and alternate contact sent the updated genotyping policy and were requested to amend their protocol prn to remain in compliance.

Action Items:	<p>Committee approved renewal.</p> <p>& - Committee approved renewal.</p> <p>and - Committee approved renewal.</p> <p>- Committee approved renewal.</p> <p>- Committee approved renewal.</p> <p>& - Committee approved renewal.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td> </tr> <tr> <td>Withhold Approval</td><td>0</td> </tr> <tr> <td>Abstain</td><td>0</td> </tr> <tr> <td>Present</td><td>19</td> </tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	C	[REDACTED]	03-31-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed animal monitoring, anesthesia checks, and glucose testing times. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
2. # [REDACTED]	D Y	[REDACTED]	03-31-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
3. # [REDACTED]	D Y	[REDACTED]	03-31-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified CVS was notified and was in collaboration with change in timing of administration. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0				
IACUC Vote													
Approval	21												
Withhold Approval	0												

	Abstain	0												
	Present	21												
4. #	D			03-31-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:														
a. Changed wording on surgeon qualification.														
Additional discussion during the meeting included:														
a. None.														
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>					IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote														
Approval	21													
Withhold Approval	0													
Abstain	0													
Present	21													
5. #	D Y			03-31-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:														
a. None.														
Additional discussion during the meeting included:														
a. None.														
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>21</td></tr></table>					IACUC Vote		Approval	20	Withhold Approval	0	Abstain	1	Present	21
IACUC Vote														
Approval	20													
Withhold Approval	0													
Abstain	1													
Present	21													
6. #	C			03-31-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:														
a. None.														
Additional discussion during the meeting included:														
a. Changed from D to E, added fasting														
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>					IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote														
Approval	21													
Withhold Approval	0													
Abstain	0													
Present	21													
7. #	D Y			03-31-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:														
a. None.														
Additional discussion during the meeting included:														
a. None.														
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>					IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote														
Approval	21													
Withhold Approval	0													
Abstain	0													
Present	21													
8. #	D Y			03-31-2022										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.


IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 02-24-2022	
2. 02-24-2022	
3. 02-25-2022	
4. 03-02-2022	
5. 03-21-2022	
6. 03-21-2022	
7. 04-20-2022	

Discussion:	<ul style="list-style-type: none"> 1. Normal wear and tear. Work order placed for touch up painting. 2. Tabled from last meeting - Most deficiencies are normal wear and tear of the building. Work orders have been placed. Husbandry deficiencies noted are increased intervals of tasks compared to SOP due to recent short staffing issues. No animal welfare concerns noted. 										
Action:	<ul style="list-style-type: none"> 1. Actions approved by the committee. 2. Action approved by the committee. 										
<table> <tr> <th colspan="2">IACUC Vote</th></tr> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 04-27-2021	LAB	
2. 06-23-2021	LAB	
3. 07-15-2021	LAB	
4. 09-29-2021	LAB	
5. 10-21-2021	LAB	
6. 02-09-2022	LAB	
7. 02-14-2022	LAB	
8. 02-22-2022	LAB	
9. 03-03-2022	LAB	
10. 03-16-2022	LAB	
11. 03-16-2022	LAB	
12. 03-18-2022	LAB	

13. 03-18-2022	LAB	
14. 03-23-2022	LAB	
15. 03-23-2022	LAB	
16. 03-28-2022	LAB	
17. 11-17-2021	PAM	
18. 02-02-2022	PAM	
19. 02-24-2022	PAM	
20. 02-28-2022	PAM	
21. 03-16-2022	PAM	
22. 03-18-2022	PAM	

Discussion:	19. Post-op records were not clear and there was pre-printed information that was incorrect. 21. PI's records could not account for one animal.
Action:	19. Lab was provided re-training on post-op record documentation. 21. PI provided re-training on record documentation for tracking animal movement.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:				
Inspection Date	Agency	Location	Summary	Discussion
1. 03-16-2022	USDA	Site 1: Focused	Focused inspection 3/16, 3/17 in response to PETA complaint "No non-compliant items."	FYI
2. 03-16-2022	USDA	Site 1: Focused	Focused inspection 3/16, 3/17, 3/22 Report pending	Missing and unaccounted mouse; lab's accounting procedures revised and staff retrained.
3. 03-16-2022	USDA	Site 2: Routine	Routine inspection 3/16, 3/17 "No non-compliant items."	FYI

XV. Other Discussion Items:

Topic	
IACUC Policy-15 "UC Davis Animal Care Program Event and Emergency Reporting Policy"	
Discussion:	None.
Action:	Approved.
IACUC Policy-24 "Use of UC Davis Facilities by Non-UC Davis Personnel"	
Discussion:	None.
Action:	Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

April 14, 2022
Meeting Minutes

[\[regular view\]](#) | [VA view](#)

Attendance:

Present:

M097, M222, M111, M042, A095, M092, A019, M119, M087, A109, M110, M226, M093, A013, M024, M001, M114

Excused:

M009, M102, M090, M004, M016, M223, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

1		Category: D										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI. Additional discussion during the meeting included: a. Voted to send to DMR.												
<table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	18											
2.		Category: D Y										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending responses from PI from previous meeting. Additional discussion during the meeting included: a. Remains tabled.												
<table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	18											

III. Amendments Tabled From Previous Meetings:

1		Category: D
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Based on pathology results, CVS worked with PI to provide additional monitoring procedures and plans to minimize potential adverse effects. CVS will shadow the next surgeries to provide additional		

support.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

[REDACTED]

Action: On going investigation reviewing records, SOPs, and tracking of animals.

[REDACTED]

Action: Portable chicken field coop w/out bottom placed to mimic actual practice and effect on cover crops. Chickens injured due to escape under sidewalls resulting from uneven deep field rows.

[REDACTED]

Action: The HVAC system needs to be repaired. Arrangements were made to move the animals to another facility. Animals were moved to the new facility and no animal welfare concerns were noted. Originating facility received a PAM for not following SIC/TIC policy by contacting the AV when it was first noticed.

[REDACTED]

Action: Trout feeder out of place, unknown cause; 1 trout mortality. IACUC staff will visit monthly.

[REDACTED]

Action: HVAC did not shut off and temp alarm failure. 1 mortality. Under investigation.

[REDACTED]

Action: Dehiscence following following osmotic pump insertion; 10 mice. IACUC Staff addressing through PAM and amendments

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	04-06-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- Add alternate contact other than PI.
- Clarification of non-pharmaceutical agents.
- Congruency between drug chart and procedures.
- Clarification of anesthesia monitoring.
- Correct cut and paste error.

Additional discussion during the meeting included: a. None.			
2. #	D Y		04-07-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. MOUs requested and provided. Additional discussion during the meeting included: a. None.			
3. #	D		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer's discussion with Committee member.			
4. #	D		04-11-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Additional Section 14a edits to remove standard of care and ensure Client Consent is congruent. Additional discussion during the meeting included: a. None.			
5. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of monitoring while off-site. Additional discussion during the meeting included: a. Pending Occ Health.			
6. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
7. #	D		04-14-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on humane endpoints. Additional discussion during the meeting included: a. None.			
8. #	D Y		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Terminology clarification. b. Listed drugs in section 14b. Additional discussion during the meeting included: a. IACUC requested sections be reorganized and extraneous information removed. Approved for DMR.			

9. # [REDACTED]	C	[REDACTED]	04-01-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	04-13-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Numbers clarification.</p> <p>b. Updated VHSS added.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI.</p>			
12. # [REDACTED]	D	[REDACTED]	04-14-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on the assessment of cytokines on sensory responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C	[REDACTED]	04-14-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarification on milk disposition and withdrawal</p>			
14. # [REDACTED]	C	[REDACTED]	04-14-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D	[REDACTED]	04-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on adverse events of compounds and pharmaceutical grade compounds.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C Y	[REDACTED]	04-11-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified housing length, feeding, and location of study.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
17. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending reviewer.</p>			
18. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
19. #	C		04-14-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		04-07-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed monitoring for dehydration. Added VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarification of timeline and possible side effects</p>			
22. #	C		04-14-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarify methods of sample collection</p>			
23. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarification of containment procedures for Beef operations</p>			
24. #	C Y		04-04-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed USDA coverage and adding saline as a drug.</p>			

Additional discussion during the meeting included: a. None.			
25. #	C		04-12-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified group numbers and housing. Additional discussion during the meeting included: a. None.			
26. #	C		03-31-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified housing. Additional discussion during the meeting included: a. None.			
27. #	B		04-14-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
28. #	C		04-05-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
29. #	C		04-14-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding water regulation trial completion. Additional discussion during the meeting included: a. Pending PI response.			
2. #	D Y		04-14-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA Amendment approval. b. Potential adverse effects of vaccine; none anticipated. Additional discussion during the meeting included: a. None.			
3. #	D Y		04-14-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
4. #	C		04-07-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
5. #	D Y		04-14-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed reasons for route of administration and sterility of injection. Additional discussion during the meeting included: a. None.			
6. #	C		04-11-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
7. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA approval. Additional discussion during the meeting included: a. Remains in DMR.			
8. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding number of animals and max duration. Additional discussion during the meeting included: a. Remains in DMR.			
9. #	D		04-07-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Added VHSS specific for slow release pellets. Additional discussion during the meeting included: a. None.			
10. #	C		04-12-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
11. #	D Y		04-07-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

12. # [REDACTED]	C	[REDACTED]	04-07-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified cell culture vs animal work.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	D	[REDACTED]	04-01-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	E	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending responses from PI from previous meeting.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
15. # [REDACTED]	E	[REDACTED]	04-11-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	D	[REDACTED]	04-04-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D	[REDACTED]	04-14-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	C Y	[REDACTED]	04-11-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	C	[REDACTED]	03-31-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 215 Administrative and Veterinary Verification Amendments were processed since the last IACUC

meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	E	[REDACTED]	04-28-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Reviewer.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
2. # [REDACTED]	D	[REDACTED]	05-12-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers, procedures, and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewers. Voted to send to DR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
3. # [REDACTED]	C	[REDACTED]	04-14-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarification of visual and auditory and olfactory contact for conspecifics</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
4. # [REDACTED]	D	[REDACTED]											

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Pending PI.

Additional discussion during the meeting included:

- a. Voted to send to DMR.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	16

5. #	D		04-14-2022
------	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarified acronyms, injection volumes, and techniques. Updated drug section. Specified age range.

Additional discussion during the meeting included:

- a. None.

IACUC Vote

Approval	17
Withhold Approval	0
Abstain	0
Present	17

6. #	D		04-14-2022
------	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Added VHSS.

Additional discussion during the meeting included:

- a. None.

IACUC Vote

Approval	17
Withhold Approval	0
Abstain	0
Present	17

7. #	D Y		04-14-2022
------	-----	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Pending Radiation Safety review.

Additional discussion during the meeting included:

- a. None.

IACUC Vote

Approval	16
Withhold Approval	0
Abstain	0
Present	16

8. #	D		04-14-2022
------	---	--	------------

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified acronyms and updated PI training.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
9. #	D		04-15-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending question from reviewer.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
10. #	D		04-14-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified acronyms and added VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	C	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	E	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	C	[REDACTED]	04-28-2020	04-14-2022	04-28-2023
	E	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D	[REDACTED]	04-14-2020	04-14-2022	04-14-2023

			04-21-2020	04-14-2022	04-21-2023
	C		04-24-2020	04-14-2022	04-24-2023
	D		04-16-2020	04-14-2022	04-16-2023
	D Y		04-16-2020	04-14-2022	04-16-2023
	C		04-21-2020	04-14-2022	04-21-2023
	C		04-16-2020	04-14-2022	04-16-2023
	C		04-16-2020	04-14-2022	04-16-2023
	C Y		04-16-2020	04-14-2022	04-16-2023
	C		04-20-2020	04-14-2022	04-20-2023
	C		04-16-2020	04-14-2022	04-16-2023
	C		04-21-2020	04-14-2022	04-21-2023
	C		04-16-2020	04-14-2022	04-16-2023
	E		04-17-2020	04-14-2022	04-17-2023
	D		04-17-2020	04-14-2022	04-17-2023
	D		04-16-2020	04-14-2022	04-16-2023
	C		04-16-2020	04-14-2022	04-16-2023
	C		04-29-2020	04-14-2022	04-29-2023
	D		04-16-2020	04-14-2022	04-16-2023
	C Y		04-29-2020	04-14-2022	04-29-2023
	D Y		04-16-2020	04-14-2022	04-16-2023
	D Y		04-16-2020	04-14-2022	04-16-2023
	C		04-20-2020	04-14-2022	04-20-2023
	D		04-17-2020	04-14-2022	04-17-2023
	D		04-27-2020	04-14-2022	04-27-2023
	D Y		04-29-2021	04-14-2022	04-29-2023
	D Y		04-29-2021	04-14-2022	04-29-2023

	D		04-26-2021	04-14-2022	04-26-2023
	D		04-29-2021	04-14-2022	04-29-2023
	C Y		04-29-2021	04-14-2022	04-29-2023
	D		04-28-2021	04-14-2022	04-28-2023
	D		04-29-2021	04-14-2022	04-29-2023
	C		04-29-2021	04-14-2022	04-29-2023
	D Y		04-29-2021	04-14-2022	04-29-2023
	C		04-29-2021	04-14-2022	04-29-2023
	C		04-27-2021	04-14-2022	04-27-2023
	D		04-29-2021	04-14-2022	04-29-2023
	C		04-29-2021	04-14-2022	04-29-2023

Discussion:	<p>updated genotyping policy sent to PI and alternate contact. Amendments to be submitted prn to remain in compliance.</p> <p>- protocol may qualify for ethical review as opposed to a protocol review at de novo. AV looking into MOU with vet listed in section 11.</p> <p>-permit on protocol is expired. PI provided updated permit.</p> <p>, and - one staff member is pending their OHSS renewal process; pending in person appointment.</p>										
Action Items	<p>, and</p> <p>-annual renewals approved.</p> <p>-annual renewal approved.</p> <p>-committee approved adding updated permit to protocol and approved the annual renewal.</p> <p>and -annual renewal approved.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>16</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1. #	D Y		04-21-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Discussed pharmaceutical grade nature of the tissue glue requested.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	16

2. # [REDACTED]	D Y [REDACTED]	04-14-2022
-----------------	----------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Modifications to methods seem appropriate at CVS recommendations.

Additional discussion during the meeting included:

- a. Committee voted to approve.

IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16

3. # [REDACTED]	D [REDACTED]	04-28-2022
-----------------	--------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Pending PI.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	16

4. # [REDACTED]	E [REDACTED]	06-06-2022
-----------------	--------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Pending PI.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	16

5. # [REDACTED]	D Y [REDACTED]	04-14-2022
-----------------	----------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. No animal welfare concerns. Hypersalivation was momentary.

Additional discussion during the meeting included:

- a. Committee voted to approve.


<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 15 Withhold Approval 0 Abstain 0 Present 15 </div>		
6. # [REDACTED]	D Y [REDACTED]	04-14-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Discussed PAM.		
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 15 Withhold Approval 0 Abstain 0 Present 15 </div>		
7. # [REDACTED]	D [REDACTED]	04-14-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Committee voted to Approve.		
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 16 Withhold Approval 0 Abstain 0 Present 16 </div>		
8. # [REDACTED]	D [REDACTED]	04-28-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI. Additional discussion during the meeting included: a. Voted to send to DMR.		
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 16 </div>		

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 08-18-2021	[REDACTED]
2. 11-16-2021	[REDACTED]
3. 01-13-2022	[REDACTED]
4. 01-21-2022	[REDACTED]
5. 01-25-2022	[REDACTED]
6. 03-22-2022	[REDACTED]
7. 04-07-2022	[REDACTED]

Discussion:	7. Only one room was inspected. The room had not been used in a while and was needed to support animals coming from another facility.										
Action:	7. Room was appropriate and report approved.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>15</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>15</td></tr> </tbody> </table>		IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote											
Approval	15										
Withhold Approval	0										
Abstain	0										
Present	15										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 11-05-2021	LAB	
2. 01-27-2022	LAB	
3. 02-22-2022	LAB	
4. 02-24-2022	LAB	
5. 03-17-2022	LAB	
6. 04-06-2022	LAB	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>16</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1) IACUC Policy-02 "Training Requirements for Personnel Working with Live, Vertebrate Animals Used in Research and/or Teaching"	
Discussion:	None.
Action:	Approved.
2) IACUC Policy-51 "Use of Shelter Animals in Research and Teaching Projects"	
Discussion:	None.
Action:	Approved.
3) IACUC-07 "Animal Care and Use Protocol/Amendment Review and Renewal Process"- with comments, for discussion.	
Discussion:	Discussed requirements for FC review.
Action:	Returned to the subcommittee with added reviewers.
4) SAPR Checklist	
Discussion:	Pandemic and effects on staffing, training procedures, emergency management procedures, OLAW inspection waiver; campus security. All IACUC members completed assigned training.
Action:	Approved.

5) SAPR Executive Report	
Discussion:	None.
Action:	Approved.
7) SAPR Signature page	
Discussion:	None.
Action:	Approved.
8) New PI Maintained form for existing project [REDACTED]	
Discussion:	None.
Action:	Approved.
9) Guests, [REDACTED] and [REDACTED] and [REDACTED] from CVS	
Discussion:	None.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

April 28, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M222, M102, M111, M042, M092, A019, M087, A109, M110, M093, A013, M016, M024, M223, M001, M114

Excused:

M090, A095, M004, M119, M226, M112

Guests:

M224, M116, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the February 17, 2022, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

The IACUC reviewed and approved the March 17, 2022, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

II. Protocols Tabled From Previous Meetings:

1. [REDACTED]	Category: D Y										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending responses from PI. Additional discussion during the meeting included: a. Tabled.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

III. Amendments Tabled From Previous Meetings:

1 [REDACTED]	Category: D
--------------	-------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification on number of procedures performed.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

Mouse handling

Action: Anonymous report from student that lab members were not correctly performing IP injections in mice. IACUC staff investigating; more information is needed in order to evaluate.

Dairy

Action: Path report of April 6 cow found dead determined to be oleander poisoning following Picnic Day events.

CNPRC follow-up

Action: Alarm failure investigation continuing. New box replacement and redundant system discussed.

ASUCD resolution SR29_SQ22

Action: ASUCD asking that campus no longer support research. Working with Stat Comm on response. IACUC discussed need for transparency and education. Faculty member shared same group had tried to cancel PE program.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. [REDACTED]	E	[REDACTED]	04-28-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Suggested wording change. Additional discussion during the meeting included: a. None.			
2. [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA. Additional discussion during the meeting included:			

a. Voted to stay in DMR.			
3. [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
4. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer's discussion with Committee member.</p>			
5. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
6. # [REDACTED]	C	[REDACTED]	04-27-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
8. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Terminology clarification.</p> <p>b. Listed drugs in section 14b.</p> <p>Additional discussion during the meeting included:</p> <p>a. Terminology clarification.</p> <p>b. Listed drugs in section 14b.</p>			
9. # [REDACTED]	C	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
10. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers and standard of care.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
11. # [REDACTED]	C	[REDACTED]	04-28-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	04-28-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	D	[REDACTED]	04-21-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of single housing justification.</p> <p>b. Clarification of surgeons</p> <p>c. statement that investigators follow humane endpoints policy.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
15. # [REDACTED]	C	[REDACTED]	04-28-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarification of experimental design</p>			
16. # [REDACTED]	C	[REDACTED]	04-19-2022

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarification of weaning age</p>			
17. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. IACUC will require an MOU if this is not eligible for an ethical review with funding.</p>			
18. #	D		04-15-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Updated drug table and added VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D Y		04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Statement included that the water regulation won't be done without a water regulation trial.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. #	D Y		04-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. #	D Y		04-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	D Y		04-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. #	D Y		04-26-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D Y	[REDACTED]	04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified milking is done by hand, not mechanically.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	04-22-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D Y	[REDACTED]	04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified milking is done by hand, not mechanically.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D Y	[REDACTED]	04-21-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed adding adhesive to the Non-Pharmaceutical Grade drug section.</p> <p>Additional discussion during the meeting included:</p> <p>a. Decided to add tissue glues/adhesives to the Non-Pharmaceutical Grade drug section.</p>			
10. # [REDACTED]	D Y	[REDACTED]	04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified milking is done by hand, not mechanically.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D	[REDACTED]	04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified which agents will be used.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
13. # [REDACTED]	D Y	[REDACTED]	04-25-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Added in verbiage listing maximum number of animals and amount of time potentially impacted by the amendment.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D Y	[REDACTED]	04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed review and provided VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D Y	[REDACTED]	04-18-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety completed review and protocol VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C Y	[REDACTED]	04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of gestational age.</p> <p>Additional discussion during the meeting included:</p> <p>a. Request to have volume clarified.</p> <p>b. Remains in DMR.</p>			
18. # [REDACTED]	C	[REDACTED]	04-25-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on unexpected death.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D Y	[REDACTED]	04-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	D	[REDACTED]	04-21-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D	[REDACTED]	04-27-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
22. #	E		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
23. #	D		04-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending IACUC reviewer.</p> <p>b. Remains in DMR.</p>			
25. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
26. #	D		04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal number justification, tumor size be monitored and euthanasia criteria.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to Approve.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 221 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	04-28-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	18
Withhold Approval	0

	Abstain	0												
	Present	18												
2. #	E			04-28-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:														
a. None.														
Additional discussion during the meeting included:														
a. voted to approve with change in category														
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>					IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote														
Approval	18													
Withhold Approval	0													
Abstain	0													
Present	18													
3. #	C			04-28-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:														
a. Question entered regarding sexing birds and sample sizes.														
b. Request for clarification of who will perform blood collection														
Additional discussion during the meeting included:														
a. pending PI, request DMR.														
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>					IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote														
Approval	0													
Withhold Approval	0													
Abstain	0													
Present	18													
4. #	D Y			04-29-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:														
a. None.														
Additional discussion during the meeting included:														
a. Additional review time requested by IACUC reviewer.														
b. Approved for DMR.														
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>					IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote														
Approval	0													
Withhold Approval	0													
Abstain	0													
Present	18													
5. #	D Y			05-10-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:														
a. Clarify anesthesia and lymph node biopsy occur contemporaneous with the blood draws.														
Additional discussion during the meeting included:														
a. None.														
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>					IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote														
Approval	0													
Withhold Approval	0													
Abstain	0													
Present	18													
6. #	D Y			04-28-2022										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification regarding sex and number selection.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

7. #

D Y

05-05-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

8. #

D

06-06-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Pending BUA amendment.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

9. #

D

04-28-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarified drug concentration.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

10. #

D Y

04-28-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

a. None. <div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 18 Withhold Approval 0 Abstain 0 Present 18 </div>			
11. # [REDACTED]	C	[REDACTED]	05-12-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification requested regarding time of euthanasia. Housing location to be inspected by IACUC staff and CVS. Additional discussion during the meeting included: a. Voted to send to DMR. <div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 19 </div>			
12. # [REDACTED]	D	[REDACTED]	06-09-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BIO and Reviewer. Additional discussion during the meeting included: a. Voted to DMR. <div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 19 </div>			

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	D Y	[REDACTED]	04-30-2020	04-28-2022	04-30-2023
	D Y		04-30-2020	04-28-2022	04-30-2023
	C		04-16-2020	04-28-2022	04-16-2023
	C		04-30-2020	04-28-2022	04-30-2023
	E		05-01-2020	04-28-2022	05-01-2023
	C		04-16-2020	04-28-2022	04-16-2023
	D		04-30-2020	04-28-2022	04-30-2023

	D Y		5-04-2020	04-28-2022	05-04-2023
	D Y		4-30-2020	04-28-2022	04-30-2023
	D		5-07-2020	04-28-2022	05-07-2023
	C		5-11-2020	04-28-2022	05-11-2023
	D		4-30-2020	04-28-2022	04-30-2023
	C		5-04-2020	04-28-2022	05-04-2023
	C		5-13-2020	04-28-2022	05-13-2023
	D		4-30-2020	04-28-2022	04-30-2023
	D Y		5-01-2020	04-28-2022	05-01-2023
	E		5-04-2020	04-28-2022	05-04-2023
	C		5-11-2021	04-28-2022	05-11-2023
	D Y		5-05-2021	04-28-2022	05-05-2023
	D		5-06-2021	04-28-2022	05-06-2023
	D		5-11-2021	04-28-2022	05-11-2023
	C		5-03-2021	04-28-2022	05-03-2023
	C		5-12-2021	04-28-2022	05-12-2023
	D		5-02-2021	04-28-2022	05-02-2023
	C		5-11-2021	04-28-2022	05-11-2023
	C Y		5-13-2021	04-28-2022	05-13-2023
	C Y		5-13-2021	04-28-2022	05-13-2023
	D		5-13-2021	04-28-2022	05-13-2023
	B		4-30-2021	04-28-2022	04-30-2023
	C Y		5-13-2021	04-28-2022	05-13-2023
	C		5-13-2021	04-28-2022	05-13-2023
	D Y		5-13-2021	04-28-2022	05-13-2023

	D		04-30-2021	04-28-2022	04-30-2023
	D		05-13-2021	04-28-2022	05-13-2023
	C		05-12-2021	04-28-2022	05-12-2023
	D		05-13-2021	04-28-2022	05-13-2023
	B		05-11-2021	04-28-2022	05-11-2023
	B		05-11-2021	04-28-2022	05-11-2023
	B		05-11-2021	04-28-2022	05-11-2023

Discussion:	<p>expired permit on protocol. PI provided an updated permit.</p> <p>one person in process of updating their OHSS status; final stop appt.</p> <p>and - sent the PI and alt. contact a copy of the updated genotyping policy and requested staff be retrained on the policy and protocol amended as needed to remain in compliance.</p> <p>- and OHSS is expired. Exemption provided</p>
Action Items:	<p>-committee approved annual renewal and updating the protocol.</p> <p>-committee approved renewals.</p> <p>and - committee approved the protocol.</p> <p>- committee approved renewal with exemption.</p>

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1. #	D		04-29-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Modification requested to clarify amendment is only for animals needing to be transferred prior to expiration date. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
2. #	D Y		05-10-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify procedural timing. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
3. #	C		05-17-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Voted for DR, Pending inspection of new methods and investigation by IACUC Members, r													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
4. #	D		04-28-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
5. #	E		05-12-2022										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Committee requests additional scientific documentation for not using post-op analgesia.

Additional discussion during the meeting included:

- a. Tabled.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

6. #	C		04-28-2022
------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 10-11-2021	
2. 03-30-2022	
3. 04-13-2022	
4. 04-25-2022	

Discussion:	2. Most deficiencies due to normal wear and tear. Staff deficiency due to student not completing OHSS process.
Action:	2. Committee approved report and the facility's plan of action.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 05-18-2021	LAB	
2. 01-19-2022	LAB	
3. 02-07-2022	LAB	
4. 04-14-2022	LAB	
5. 04-19-2022	LAB	
6. 04-25-2022	LAB	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. IACUC Policy-09 "Use of Non-Pharmaceutical-Grade Compounds in Animals"	
Discussion:	None.
Action:	Approved.
2. IACUC Policy-27 "Fluid Regulation Policy for Nonhuman Primates"	
Discussion:	None.
Action:	Approved.
3. IACUC Policy-34 "Guidelines for Animal Care in Chronically Implanted Nonhuman Primates"	
Discussion:	None.
Action:	Approved.
4. PI maintain request	
Discussion:	PI maintain status was requested by TRACS due to staffing shortage.
Action:	Committee voted to approve.
5. IACUC inspection participation	
Discussion:	Reminded members of IACUC Charge expectations; COVID precautions and accommodations; OHSS.
Action:	FYI.
6. Fluid 1st quarter report	
Discussion:	One incident of noncompliance already documented on facility report.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

May 12, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M222, M111, M042, A095, M004, M092, A019, M119, M087, A109, M110, M226, M093, A013, M016, M024, M223, M001, M114

Excused:

M009, M097, M102, M090, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the March 3, 2022, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

The IACUC reviewed and approved the March 31, 2022, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

II. Protocols Tabled From Previous Meetings:

1. # [REDACTED]	Category: D Y										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI agreed to have an acclimation period of 5-7 days for consistency.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

III. Amendments Tabled From Previous Meetings:

1. # [REDACTED]	Category: E
-----------------	-------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. AV met with the PI and discussed publications showing an impact using systemic and local anesthetics.

Additional discussion during the meeting included:

- a. Committee voted to approve as written and remains category E.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

1. FYI - VASDHS oversight audit

Action: None.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul style="list-style-type: none">a. Still pending BUA. Additional discussion during the meeting included: <ul style="list-style-type: none">a. Remains in DMR.			
2. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul style="list-style-type: none">a. Clarification of procedures and adverse events. Additional discussion during the meeting included: <ul style="list-style-type: none">a. Pending PI.			
3. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul style="list-style-type: none">a. None. Additional discussion during the meeting included: <ul style="list-style-type: none">a. Pending reviewer's discussion with Committee reviewer.			

4. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of locations and monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
5. # [REDACTED]	C	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
6. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Terminology clarification.</p> <p>b. Listed drugs in section 14b.</p> <p>Additional discussion during the meeting included:</p> <p>a. Information needs to be moved to correct sections, especially section 13 and 15. IACUC staff to work with PI to modify, No change in text, just text location, then approve.</p>			
7. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending MOU.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending MOU from PI.</p>			
8. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	C	[REDACTED]	05-02-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	C	[REDACTED]	04-28-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. clarification of how birds are sexed.</p> <p>b. Clarification of who will be doing blood collection</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
11. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending MOU.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending MOU from PI.</p>			
12. # [REDACTED]	D Y	[REDACTED]	04-29-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Recommendation to remove extraneous details.</p> <p>b. Clarification of needle sizes; clarification of superovulated or electoporated rationale; clarification of survival vs terminal procedures</p> <p>c. Analgesic clarification.</p> <p>d. Potential adverse effect clarifications.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	D Y	[REDACTED]	05-10-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Sedation and biopsy clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending MOU.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending MOU from PI.</p>			
15. # [REDACTED]	D Y	[REDACTED]	05-05-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on single housing.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. Discussed analgesia.</p>			
17. # [REDACTED]	C	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. AV and IACUC staff along with TRACS inspected proposed rooms with PI and reviewed PI requirement.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

18. # [REDACTED]	C	[REDACTED]	05-09-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarified training on feces collection and disposal</p>			
19. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarified possible catheter events.</p>			
20. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified timeline, added VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	C	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Added VHSS</p>			
23. # [REDACTED]	C	[REDACTED]	05-02-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on adverse events and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Discussion on animal number justification, remains in DMR.</p>			
25. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarification of anesthetic routes/methods and possible after effects</p>			
26. # [REDACTED]	C Y	[REDACTED]	05-12-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Chemical safety confirmed no VHSS required for Molnupiravir.

Additional discussion during the meeting included:

- a. None.

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	04-29-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. PI clarified the specific animals needing to be transferred due to protocol expiring before renewal is approved. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
2. # [REDACTED]	D Y	[REDACTED]	05-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarify timing. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
3. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
4. # [REDACTED]	D	[REDACTED]	05-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
5. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Clarification of adjuvant, and its use, and inactivation of agents/protein purification 			
6. # [REDACTED]	D Y	[REDACTED]	04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
7. # [REDACTED]	D Y	[REDACTED]	05-10-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. #	C Y		05-12-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
9. #	D Y		04-28-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
10. #	C		05-02-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
11. #	C		05-12-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
12. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. inspection needed Additional discussion during the meeting included: a. None.			
13. #	C		05-12-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
14. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Reviewer.			
15. #	C		05-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

16. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety confirmed no VHSS was required.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animals numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
19. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
20. # [REDACTED]	D	[REDACTED]	05-02-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D	[REDACTED]	05-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]		[REDACTED]	05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	E	[REDACTED]	05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	D	[REDACTED]	05-12-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D		05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	C		05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. New VHSS</p>			
27. #	D Y		04-28-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	D		05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
30. #	D Y		05-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of gestational age.</p> <p>b. Volume clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. #	D Y		05-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI clarified original numbers justification for main protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	D Y		05-02-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. #	D Y		05-09-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
34. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
35. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
36. # [REDACTED]	C	[REDACTED]	05-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
37. # [REDACTED]	C Y	[REDACTED]	05-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed review and provided a VHSS for the original protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
38. # [REDACTED]	C Y	[REDACTED]	05-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed review of amendment and original protocol. VHSS provided for amendment and protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
39. # [REDACTED]	C Y	[REDACTED]	05-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer confirmed no VHSS was required.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
40. # [REDACTED]	E	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. clarification of monitoring period vs terminal limitation.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI.</p>			
41. #22491	D	add adenine in chow	05-11-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
42. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify groups. Additional discussion during the meeting included: a. Reviewer request additional time to review. Remains in DMR			
43. #	D		05-12-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Requested change in term used. Additional discussion during the meeting included: a. None.			
44. #	D		05-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
45. #	D Y		05-10-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
46. #	D		05-10-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed review and provided VHSS. Additional discussion during the meeting included: a. None.			
47. #	C		04-27-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 146 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date
----------	----------	-------	------

1. #	D Y		Approved 06-09-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify study location. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
2. #	D		05-26-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Reviewer.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
3. #	D Y		05-12-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
4. #	D		05-12-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
5. #	D		05-26-2022										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Sx protocol expiring before next meeting. Investigator concerned about JIT. Requested DR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

6. # [REDACTED]	E	[REDACTED]	05-12-2022
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

7. # [REDACTED]	D	[REDACTED]	05-12-2022
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. define abbreviation.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

8. # [REDACTED]	D	[REDACTED]	05-12-2022
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Replacement protocol. Review completed by safety officers and VHSS updated.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

9. # [REDACTED]	D Y	[REDACTED]	06-09-2022
-----------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Provide additional rationale to support requested timeline.

b. Clarification of reward.

Additional discussion during the meeting included:

a. Pending PI.
Approved for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

10. #	C Y		05-12-2022
-------	-----	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

11. #	D Y		05-12-2022
-------	-----	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarify pairing logistics.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

12. #	D Y		05-12-2022
-------	-----	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification provided regarding pain scoring and number of studies per animal.

Additional discussion during the meeting included:

a. Committee approved protocol.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

13. #	D		05-12-2022
-------	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Discussed cage labeling and daily checks as well as proper waste disposal.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20

Withhold Approval		0
Abstain		0
Present		20

14. #	D Y		05-12-2022
-------	-----	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		05-14-2020	05-12-2022	05-14-2023
	C		05-14-2020	05-12-2022	05-14-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	D		05-14-2020	05-12-2022	05-14-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	C		05-01-2020	05-12-2022	05-01-2023
	C		05-15-2020	05-12-2022	05-15-2023
	C		05-15-2020	05-12-2022	05-15-2023
	C		05-14-2020	05-12-2022	05-14-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	Y		05-14-2020	05-12-2022	05-14-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	C		05-12-2020	05-12-2022	05-12-2023
	D		05-14-2020	05-12-2022	05-14-2023
	C		05-19-2020	05-12-2022	05-19-2023
	C		05-19-2020	05-12-2022	05-19-2023

	C		05-27-2021	05-12-2022	05-27-2023
	D Y		04-05-2021	05-12-2022	04-05-2023
	D		05-27-2021	05-12-2022	05-27-2023
	D Y		05-27-2021	05-12-2022	05-27-2023
	D		05-18-2021	05-12-2022	05-18-2023
	C		05-27-2021	05-12-2022	05-27-2023
	C		05-21-2021	05-12-2022	05-21-2023
	E		05-26-2021	05-12-2022	05-26-2023
	C Y		05-17-2021	05-12-2022	05-17-2023
	D		05-21-2021	05-12-2022	05-21-2023
	C Y		05-27-2021	05-12-2022	05-27-2023
	D		05-27-2021	05-12-2022	05-27-2023
	D		05-27-2021	05-12-2022	05-27-2023
	D Y		05-27-2021	05-12-2022	05-27-2023
	D Y		05-24-2021	05-12-2022	05-24-2023
	D		05-17-2021	05-12-2022	05-17-2023
	C		05-27-2021	05-12-2022	05-27-2023
	D		05-27-2021	05-12-2022	05-27-2023
	D		05-25-2021	05-12-2022	05-25-2023
	C Y		05-27-2021	05-12-2022	05-27-2023
	C		05-27-2021	05-12-2022	05-27-2023
	C		05-21-2021	05-12-2022	05-21-2023

Discussion:	<p>_____ & _____-one staff member is in the process of updating their OHSS status pending appt.</p> <p>_____, _____, _____, _____, _____, _____, _____, _____ & _____ updated identification/genotyping policy sent to PI and alt. contact for review and training. Amendments to be submitted as needed to remain in compliance.</p>
Action Items:	<p>_____ & _____-committee approved the renewals.</p> <p>_____, _____, _____, _____, _____, _____, _____, _____ & _____ Committee approved annual renewals.</p>

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

XI. Amendments for Full Committee Review:


The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D	[REDACTED]	05-26-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Asked for #of animals affected vs total injected..</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D	[REDACTED]	05-12-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
3. # [REDACTED]	D	[REDACTED]	05-12-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of sterile prep.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	C	[REDACTED]											

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Request that hemostatic be specified. b. Confirmation of age range. c. Clarification of wording. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Discussed fact that investigator does not provide a valid scientific justification for the procedure. Further questions will be sent to investigator. 													
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
5. #	D Y		05-12-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification provided during the pre-review process which group this applies to and what has been observed thus far in the study. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Committee voted to approve. 													
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
6. #	D		05-12-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of monitoring and follow up care. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI. 													
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
7. #	D Y		05-12-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 													
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												

XII. Animal Housing/Facility Inspections:


Inspection Date	Vivarium
-----------------	----------

1. 02-28-2022		
2. 03-18-2022		
3. 03-23-2022		
4. 03-24-2022		
5. 03-31-2022		
6. 03-31-2022		
7. 04-07-2022		
8. 04-25-2022		
9. 04-28-2022		

Discussion:	3. Staff training records provided to IACUC office after response date due to PI being in the field. 4. All deficiencies due to normal wear and tear of building 5. Yearly eyewash station was missed during yearly checks. 6. Normal wear and tear in the building. 7. Facility manager reported HVAC concerns to AV a week after the issues began.
Action:	3. IACUC accepted plan moving forward to prevent deficiency. 4. Work orders have been placed. 5. Work order placed and completed. 6. Work order placed and completed. 7. Facility manager retrained on SIC/TIC requirements.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 04-11-2022	LAB	
2. 04-11-2022	LAB	
3. 04-18-2022	LAB	
4. 04-29-2022	LAB	
5. 05-01-2022	LAB	
6. 04-27-2022	PAM	
7. 04-27-2022	PAM	

Discussion:	6 & 7- Animals from previously approved protocol were not transferred to the replacement protocols.										
Action:	6 & 7 - ATS has been updated and PI was trained on ATS policy.										
<table> <tr><th colspan="2">IACUC Vote</th></tr> <tr><td>Approval</td><td>19</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>19</td></tr> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
	- holding protocol
Discussion:	None.
Action:	None.
	- holding protocol
Discussion:	226 animals placed on holding protocol until replacement protocol is approved.
Action:	None at this time.
IACUC-05 "IACUC Charge"	
Discussion:	None.
Action:	Approved.
IACUC-47 "Clinical Veterinarian Authority"	
Discussion:	None.
Action:	Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

**University of California, Davis
IACUC Business Administration System**

**May 26, 2022
Meeting Minutes**

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M222, M102, M042, A095, M092, A019, M119, M087, A109, M110, M226, M093, A013,
M016, M024, M223, M001, M114

Excused:

M111, M090, M004, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:	
Protocol	
Action: TRACS fasting event	
Protocols	&
Action: Discussed anonymous concern report. IACUC staff reviewing documents and meeting with PI next week.	
Protocol	No evidence to verify original concern.
Action: Training provided to the department. No further action.	
Protocol	
Action: Deficient incoming water tubes resulting in juvenile chinook salmon mortality. IACUC staff will conduct post approval monitoring.	
USDA courtesy notice of records turnover to NEAVS	
Action: FYI.	

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date
----------	----------	-------	------

			Approved
1. # [REDACTED]	D	[REDACTED]	05-24-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on BUA and personnel roster.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	C	[REDACTED]	05-18-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Additional clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer's discussion with Committee member.</p>			
4. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	C	[REDACTED]	05-12-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. No additional information requested but IACUC staff discussed modifying/rearranging information to better address each protocol section prompt.</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved IACUC staff to work with PI. Information needs to be moved to correct sections, especially section 13 and 15. IACUC staff to work with PI to modify, No change in text, just text location, then approve.</p>			
7. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. pending resolution of MOU vs ethical review.			
8. # [REDACTED]	C	[REDACTED]	05-13-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
9. # [REDACTED]	D	[REDACTED]	05-26-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
10. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
11. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. pending resolution of MOU vs ethical review.			
12. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. pending resolution of MOU vs ethical review.			
13. # [REDACTED]	D	[REDACTED]	05-26-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of implantation procedures. b. Clarification of dosing and route for compounds. c. Clarification of adverse effects. Additional discussion during the meeting included: a. None.			
14. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA Amendment Approval. Additional discussion during the meeting included: a. None.			
15. # [REDACTED]	C	[REDACTED]	05-17-2022

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chairing clarification.</p> <p>b. Reward clarification</p> <p>c. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
18. #	C		05-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	C		05-20-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified class names and numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D Y		05-19-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Anesthesia procedures clarified.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		05-26-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		05-26-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	C		05-26-2022

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		05-26-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified drug administration and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		05-26-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures, drugs, and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D Y		05-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. #	D		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal #s.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI response</p>			
4. #	D		05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. #	D Y		05-23-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #	D		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	C		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on terminology.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	D		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	C		05-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending inspection and wording</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	D		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		05-20-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			

14. # [REDACTED]	D	[REDACTED]	05-13-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]		[REDACTED]	05-25-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	D Y	[REDACTED]	05-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D Y	[REDACTED]	05-19-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D Y	[REDACTED]	05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	C	[REDACTED]	05-11-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	C Y	[REDACTED]	05-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D	[REDACTED]	05-19-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	C Y	[REDACTED]	05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Confirmation of same sedation as in parent protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

23. # [REDACTED]	D	[REDACTED]	05-12-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of ulceration monitoring and frequency.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	D	[REDACTED]	05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]		[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
26. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarification of routes and add VHSS</p>			
27. # [REDACTED]	D	[REDACTED]	05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed training on techniques.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. # [REDACTED]	D	[REDACTED]	05-18-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. # [REDACTED]	D Y	[REDACTED]	05-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. # [REDACTED]	D Y	[REDACTED]	05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. # [REDACTED]	D Y	[REDACTED]	05-17-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	D		05-16-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. #	E		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
34. #	D		05-18-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed alternatives to single housing.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
35. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Procedure timing clarification; maximum sedation time.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer confirmation.</p>			
36. #	D Y		05-17-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
37. #	D Y		05-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
38. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Typo correction.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending BUA.</p>			
39. #	D		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. reword and fix typos</p>			

40. # [REDACTED]	C	[REDACTED]	05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarified facility SOP will be used.</p>			
41. # [REDACTED]	C Y	[REDACTED]	05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 196 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	05-26-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on anesthesia, chemical hazards and potential adverse events.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to Approve.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	1	Present	19
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	1												
Present	19												
2. # [REDACTED]	D	[REDACTED]	05-26-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to Approve.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												

3. # [REDACTED]	D	[REDACTED]	05-26-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed laser microscopy safety and secondary methods of euthanasia.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	D	[REDACTED]	06-09-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
5. # [REDACTED]	D	[REDACTED]	05-26-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to Approve.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
6. # [REDACTED]	D Y	[REDACTED]	05-26-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
7. # [REDACTED]	D	[REDACTED]	05-26-2022										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Voted to Approve.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

8. #	D		06-05-2022
------	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Pending Reviewer.

Additional discussion during the meeting included:

a. Voted to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

9. #	D		05-26-2022
------	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification on procedures and processes.

Additional discussion during the meeting included:

a. voted to Approve.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		05-29-2020	05-26-2022	05-29-2023
	D		06-03-2020	05-26-2022	06-03-2023
	D Y		05-28-2020	05-26-2022	05-28-2023
	C Y		06-03-2020	05-26-2022	06-03-2023
	D		05-28-2020	05-26-2022	05-28-2023
	D Y		06-01-2020	05-26-2022	06-01-2023
	E		05-14-2020	05-26-2022	05-14-2023
	E		05-28-2020	05-26-2022	05-28-2023

	E		5-14-2020	05-26-2022	05-14-2023
	C		5-28-2020	05-26-2022	05-28-2023
	C Y		5-28-2020	05-26-2022	05-28-2023
	D		5-28-2020	05-26-2022	05-28-2023
			5-28-2020	05-26-2022	05-28-2023
	D		6-01-2020	05-26-2022	06-01-2023
	D Y		5-28-2020	05-26-2022	05-28-2023
	D		5-28-2020	05-26-2022	05-28-2023
	D		5-28-2020	05-26-2022	05-28-2023
	D		5-29-2020	05-26-2022	05-29-2023
	C		5-28-2020	05-26-2022	05-28-2023
	C		5-28-2020	05-26-2022	05-28-2023
	D		5-28-2020	05-26-2022	05-28-2023
	D		6-08-2020	05-26-2022	06-08-2023
	D Y		5-28-2020	05-26-2022	05-28-2023
	C		5-28-2021	05-26-2022	05-28-2023
	C		6-08-2021	05-26-2022	06-08-2023
	C		5-14-2021	05-26-2022	05-14-2023
	D		6-09-2021	05-26-2022	06-09-2023
	C		6-09-2021	05-26-2022	06-09-2023
	C		6-08-2021	05-26-2022	06-08-2023
	C		5-27-2021	05-26-2022	05-27-2023
	C		6-08-2021	05-26-2022	06-08-2023
	D		6-10-2021	05-26-2022	06-10-2023
			5-28-2021	05-26-2022	05-28-2023

	C		6-01-2021	05-26-2022	06-01-2023
	C		5-28-2021	05-26-2022	05-28-2023
	C		6-10-2021	05-26-2022	06-10-2023
	D		6-10-2021	05-26-2022	06-10-2023
	D		6-10-2021	05-26-2022	06-10-2023
	C		6-09-2021	05-26-2022	06-09-2023
	D		6-10-2021	05-26-2022	06-10-2023
	C		6-07-2021	05-26-2022	06-07-2023
	D		6-10-2021	05-26-2022	06-10-2023
	D		6-10-2021	05-26-2022	06-10-2023
	C		6-09-2021	05-26-2022	06-09-2023
	D		6-10-2021	05-26-2022	06-10-2023
	C		6-10-2021	05-26-2022	06-10-2023

Discussion:

-IACUC staff working with PI to determine if updated literature search is needed.

and at least one staff member is in process of updating their OHSS process.

-Chem safety completing a follow up review to ensure the VHSS attached are accurate.

and protocol approved for breeding, ID and/or genotyping. Updated genotyping policy sent to PI and alternate contact. Requested an amendment be submitted as needed to remain in compliance with policy. Re-training of staff should be documented.

Action Items:

-annual renewal approved.

and -annual renewals approved.

-annual renewal approved.

and annual renewals approved.

IACUC Vote

Approval 19

Withhold Approval 0

Abstain 0

Present 19

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC,

reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D	[REDACTED]	05-26-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D Y	[REDACTED]	06-09-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
3. # [REDACTED]	D Y	[REDACTED]	06-05-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Dose confirmation and correction.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	D	[REDACTED]	05-26-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Voted to Approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
5. # [REDACTED]	D Y	[REDACTED]	05-26-2022										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

6. # [REDACTED]	D Y	[REDACTED]	05-26-2022
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Chem, SCRO and BIO reviews completed. No VHSS required.

Additional discussion during the meeting included:

a. Voted to approve.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

7. # [REDACTED]	D Y	[REDACTED]	06-02-2022
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending EH&S review and confirmation.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

8. # [REDACTED]	C Y	[REDACTED]	05-26-2022
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

9. # [REDACTED]	C Y	[REDACTED]	06-23-2022
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending reviewer.

b. Approved for DMR.

<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
10. #	D		05-26-2022										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to Approve.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 02-15-2022	
2. 02-15-2022	
3. 04-19-2022	
4. 04-22-2022	
5. 04-26-2022	
6. 05-12-2022	
7. 05-19-2022	

Discussion:	5. All deficiencies were due to normal wear and tear of the building. 6. Anteroom needed to be re-lamped.										
Action:	5. Work orders have been placed. 6. Work order placed.										
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>18</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>18</td> </tr> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 11-08-2021	LAB	
2. 04-18-2022	LAB	
3. 05-13-2022	LAB	
4. 05-19-2022	LAB	
5. 05-19-2022	LAB	
6. 05-24-2022	LAB	

7. 05-24-2022	LAB		
8. 12-15-2021	PAM		
9. 03-02-2022	PAM		

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>20</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>20</td></tr> </tbody> </table>		IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	20										
Withhold Approval	0										
Abstain	0										
Present	20										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic
1. Guest: [REDACTED] and possibly [REDACTED]
Discussion: Discuss potential future parrot project.
Action: FYI.
IACUC Policy-03 "IACUC Facility Inspection Program"
Discussion: Discussed wording for whom must maintain training documentation.
Action: Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

June 09, 2022
Meeting Minutes

[\[regular view\]](#) | [VA view](#)

Attendance:

Present:

M009, M097, M222, M042, A095, M004, M092, A019, A109, M110, M226, M093, A013, M016, M223, M001

Excused:

M102, M111, M090, M119, M087, M024, M112, M114

Guests:

M224, A017

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

[REDACTED]

Action: IL-10 hypovolemic shock.

[REDACTED] & [REDACTED] Follow up meeting with PI on 6/1 and 6/8. Discussed initial reported concerns and information gathered based on talking with the PI and reviewing documents.

Action: IACUC to send a letter to PI outlining concerns and action items for PI to complete.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	06-09-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Location confirmation.			

Additional discussion during the meeting included: a. None.			
2. # [REDACTED]	D	[REDACTED]	05-31-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
3. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of additives. b. Clarification of statistical design. c. Request for MOU/ethical review. d. clarification of sample collection techniques. e. Clarification of restraint. f. removal of rumen activity device and seaweed feeding. g. Clarification of GreenFeed system. h. clarification of adverse effects. Additional discussion during the meeting included: a. Pending ethical review/MOU discussion.			
4. # [REDACTED]	C	[REDACTED]	05-31-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of drug dose, exclusion criteria, and adverse effects. Additional discussion during the meeting included: a. None.			
5. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. MOU/ethical review. b. discussion of pen effect. c. Clarification of statistics Additional discussion during the meeting included: a. Pending MOU/ethical review discussion.			
6. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. MOU vs ethical review discussion. b. clarification of veterinarian. Additional discussion during the meeting included: a. None.			
7. # [REDACTED]	C Y	[REDACTED]	06-06-2022
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of animal numbers. Additional discussion during the meeting included: a. None.			
8. # [REDACTED]	D	[REDACTED]	06-06-2022

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA amendment approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	D Y		06-09-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on maximum timeframe and confirmation with veterinarian.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	C		06-09-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	C		06-03-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed handling time.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		06-09-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified number calculations, lab housing, possibility of maternal rejection, adverse effects, and BUA information.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI responses to reviewer questions.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D		06-09-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed possibility of maternal rejection. ACU 101 refresher training completed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D		06-05-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified number justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	C		06-02-2022

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarification on sample collection</p>			
17. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA Amendment Approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	C		05-27-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	C		06-09-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		06-09-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of wording regarding time of observation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of units, animal numbers, and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	D		06-06-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		06-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. #	D		06-09-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI response</p>			
3. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response to Chem Review question.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI responses to reviewer questions.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. #	D Y		06-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #	D Y		06-05-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Dose verification.</p>			
7. #	D		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	D		06-01-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. No VHSS needed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified wording, aliquot dates, and VHSSs.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	D		06-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D		06-03-2022

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	C		06-02-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. No VHSS needed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Request for scientific justification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Request to have veterinarian discuss procedures with the investigator.</p>			
14. #	D		05-30-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer</p>			
16. #	D		06-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI verified animals were exempt from NIH guidelines and route of administration is approved in BUA. Chem safety verified VHSS for chemical hazards.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D		06-03-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	D		05-26-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	C		06-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		05-26-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
21. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of volume, non-pharm grade justification and disposition. Additional discussion during the meeting included: a. None.			
22. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of volume, non-pharm grade justification and disposition. Additional discussion during the meeting included: a. None.			
23. #	D Y		06-02-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
24. #	D Y		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify wording. Additional discussion during the meeting included: a. Clarify wording.			
25. #	C		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
26. #	C		06-03-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Location and transport clarification. b. Permit confirmation. Additional discussion during the meeting included: a. None.			
27. #			-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussion of need for MOU. Additional discussion during the meeting included: a. None.			
28. #	D		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			

Additional discussion during the meeting included: a. None.			
29. #	D		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer			
30. #	D		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Chem			
31. #	C Y		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
32. #	C Y		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
33. #	D		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
34. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Further clarification on reason for additional animals requested. Additional discussion during the meeting included: a. Pending PI.			
35. #	E		06-06-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of analgesic administration. Additional discussion during the meeting included: a. None.			
36. #	D Y		06-02-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
37. #	D Y		06-09-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of groups. b. Clarification of procedure and sedation timeframes. Additional discussion during the meeting included: a. None.			
38. #	D Y		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of groups. b. Clarification of procedure and sedation timeframes. Additional discussion during the meeting included: a. None.			
39. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification requested regarding temperature grade and potential adverse effects. Additional discussion during the meeting included: a. Remains in DMR.			
40. #	D		06-07-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
41. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of wording. Additional discussion during the meeting included: a. Pending BUA.			
42. #	D Y		06-09-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 213 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. #	C		

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending MOU discussion. Request DMR.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	15

2. #

C

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending MOU discussion. Approved for DMR.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	15

3. #

D

06-09-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	15
Withhold Approval	0
Abstain	0
Present	15

4. #

D

06-09-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of Client Consent and adverse affects.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	15
Withhold Approval	0
Abstain	0
Present	15

5. #

D

06-17-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Pending PI Response to reviewer question.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	15

6. #

C Y

06-09-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

7. #

D

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. New site pending inspection. Request DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	15

8. #

D

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Previous protocol expired. Poor communication from Investigator. Pending PI responses.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	15

9. #

D

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. New site pending inspection. Request DMR.

IACUC Vote	
Approval	0
Withhold Approval	0

	Abstain	0												
	Present	15												
10. #	D Y			06-23-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested regarding tunneling procedures and equipment removal details.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to send to DMR.</p>														
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>					IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote														
Approval	0													
Withhold Approval	0													
Abstain	0													
Present	15													
11. #	D			06-09-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed staff roster.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>														
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>14</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>14</td></tr></table>					IACUC Vote		Approval	14	Withhold Approval	0	Abstain	0	Present	14
IACUC Vote														
Approval	14													
Withhold Approval	0													
Abstain	0													
Present	14													
12. #	D			06-09-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified injection volume, terminology, and euthanasia.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>														
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>15</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>					IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote														
Approval	15													
Withhold Approval	0													
Abstain	0													
Present	15													
13. #	D			06-09-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed the use of Body Condition Scores and X-rays.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>														
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>15</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>					IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote														
Approval	15													
Withhold Approval	0													
Abstain	0													
Present	15													

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		06-17-2020	06-09-2022	06-17-2023
	D Y		06-22-2020	06-09-2022	06-22-2023
	C		06-23-2020	06-09-2022	06-23-2023
	D Y		06-11-2020	06-09-2022	06-11-2023
	C		06-22-2020	06-09-2022	06-22-2023
	D		06-11-2020	06-09-2022	06-11-2023
	D Y		06-04-2020	06-09-2022	06-04-2023
	C		06-18-2020	06-09-2022	06-18-2023
	C		06-22-2020	06-09-2022	06-22-2023
			06-24-2020	06-09-2022	06-24-2023
	D		06-11-2020	06-09-2022	06-11-2023
	C		06-11-2020	06-09-2022	06-11-2023
	D Y		06-11-2020	06-09-2022	06-11-2023
	C		06-11-2020	06-09-2022	06-11-2023
	C		06-11-2020	06-09-2022	06-11-2023
	D		06-22-2021	06-09-2022	06-22-2023
	D Y		06-24-2021	06-09-2022	06-24-2023
			06-23-2021	06-09-2022	06-23-2023
	D		06-14-2021	06-09-2022	06-14-2023
	C		06-09-2021	06-09-2022	06-09-2023
	D		06-23-2021	06-09-2022	06-23-2023
	D		06-14-2021	06-09-2022	06-14-2023
	D Y		06-24-2021	06-09-2022	06-24-2023
	D		06-24-2021	06-09-2022	06-24-2023

	D		06-22-2021	06-09-2022	06-22-2023
	D		06-23-2021	06-09-2022	06-23-2023
	D		06-24-2021	06-09-2022	06-24-2023
	C		06-24-2021	06-09-2022	06-24-2023
	C Y		06-24-2021	06-09-2022	06-24-2023
	D		06-24-2021	06-09-2022	06-24-2023
	D		06-23-2021	06-09-2022	06-23-2023
	D Y		06-24-2021	06-09-2022	06-24-2023
	D		06-24-2021	06-09-2022	06-24-2023
	B		06-11-2021	06-09-2022	06-11-2023

Discussion:	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] - protocol includes breeding, ID, and/or genotyping. Sent the PI and alternate contact the updated genotyping policy and requested an amendment be submitted as needed to remain in compliance with the policy and staff re-training be documented.
Action Items:	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] = annual renewals approved.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1. # [REDACTED]	C	[REDACTED]	06-09-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Euthanasia methods and reference updated.

IACUC Vote	
Approval	15
Withhold Approval	0
Abstain	0

	Present	15											
2. #	C		06-09-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. No VHSS needed.													
Additional discussion during the meeting included:													
a. None.													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>15</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	15												
Withhold Approval	0												
Abstain	0												
Present	15												
3. #	D Y												
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. Mitigation information requested.													
Additional discussion during the meeting included:													
a. Pending PI.													
Approved for DMR.													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	15												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 11-19-2021	
2. 01-20-2022	
3. 02-25-2022	
4. 03-22-2022	
5. 05-23-2022	
6. 05-31-2022	
7. 06-02-2022	

Discussion:	<p>5- Facility had not been used in a while. Re-inspection prior to animals arriving.</p> <p>6- Recently approved PI maintained facility re-inspected after animals arrived.</p> <p>7 -PI maintain area added 2 additional rooms. Deficiencies due to normal wear and tear of the building.</p>										
Action:	<p>5- Next inspection at regularly scheduled semi-annual interval.</p> <p>6- Next inspection at quarterly intervals.</p> <p>7 -Work orders placed. Next inspection at quarterly intervals.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>14</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>14</td></tr> </tbody> </table>		IACUC Vote		Approval	14	Withhold Approval	0	Abstain	0	Present	14
IACUC Vote											
Approval	14										
Withhold Approval	0										
Abstain	0										
Present	14										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 11-17-2021	LAB	
2. 05-31-2022	LAB	
3. 06-03-2022	LAB	
4. 06-03-2022	LAB	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>15</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>15</td></tr> </tbody> </table>		IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote											
Approval	15										
Withhold Approval	0										
Abstain	0										
Present	15										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic
1. Guest - [REDACTED]
Discussion: Prior to the meeting, completed IACUC pre-review training course with IACUC staff.
Action: Will attend one additional meeting to fulfill her Master's program requirement.
2. IACUC Policy-10 "Post Approval Monitoring Program"
Discussion: None.
Action: Approved.
3. IACUC Policy-11 "Protocol Suspension"
Discussion: None.
Action: Approved.
4. [REDACTED] holding protocol transfer
Discussion: None.
Action: None.
5. Change of CVS Scientist-in-Charge: [REDACTED] to [REDACTED]
Discussion: None.
Action: Approved.
6. IACUC review of Non University Owed Animals - meeting update
Discussion: None.
Action: None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

June 23, 2022
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M102, M111, M042, A095, M004, M092, A019, M087, M226, M093, A013, M223, M001

Excused:

M222, M090, M119, A109, M110, M016, M024, M112, M114

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

1. #		Category: D										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:												
a. None.												
Additional discussion during the meeting included:												
a. Letter will be sent by IACUC Director.												
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	15											

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:	
USDA courtesy notification	
Action: FYI - Informing UCD of records that will be released under FOIA.	
	sheep
Action: Inadvertent return to vender then returned to UCD. Notification to Bio. No Animal welfare issue.	
Action: Follow-up: Pseudomonas culture positive, acute septicemia. Biological testing at vendor level.	
Action: Deviated from protocol approved vasectomy procedure.	

Action: Mouse disposition procedures not followed.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

Broilers [REDACTED], suspected Viral Outbreak or genetic issues

Broiler chicken feed study. 18% cohort mortality.

Action Items:

CAHFS Turlock will do necropsy.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending ethical review.			
2. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending response from PI. Additional discussion during the meeting included: a. None.			
3. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
4. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending ethical review.			
5. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI is working on an MOU. Additional discussion during the meeting included: a. Pending PI.			

6. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending ethical review..</p>			
7. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending ethical review.</p>			
8. # [REDACTED]	D	[REDACTED]	06-17-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal number justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending site inspection.</p>			
10. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending site inspection.</p>			
11. # [REDACTED]	C	[REDACTED]	06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	D Y	[REDACTED]	06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI included more details regarding catheter removal and potential adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

14. # [REDACTED]	D	[REDACTED]	06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers and procedures for toxicity studies.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	C	[REDACTED]	06-22-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	06-15-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	C	[REDACTED]	06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Aligning genotyping procedure with newly approved policy.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending BUA.</p>			
20. # [REDACTED]	C	[REDACTED]	06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	C Y	[REDACTED]	06-22-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

22. # [REDACTED]	D	[REDACTED]	06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	D	[REDACTED]	06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	C	[REDACTED]	06-15-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	C Y	[REDACTED]	06-22-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI clarified number of testing being studied.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. # [REDACTED]	B	[REDACTED]	06-15-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	06-14-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
3. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			

4. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested regarding adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
5. # [REDACTED]	C	[REDACTED]	06-10-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. AV to talk with investigator.</p>			
7. # [REDACTED]	C	[REDACTED]	06-13-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D	[REDACTED]	06-22-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D	[REDACTED]	06-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C Y	[REDACTED]	06-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

13. # [REDACTED]	D Y	[REDACTED]	06-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BrdU timing and VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED]	06-22-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]		[REDACTED]	06-13-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussion of MOU.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	06-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on justification for more animals.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D Y	[REDACTED]	06-22-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed eventually all animals being transferred out of [REDACTED] when building is retrofitted.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	C Y	[REDACTED]	06-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
19. # [REDACTED]	D	[REDACTED]	06-13-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding potential pain and temperature of test.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	D	[REDACTED]	06-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D	[REDACTED]	06-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
22. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested regarding numbers justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
23. # [REDACTED]	D	[REDACTED]	06-22-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI clarified hydrogen peroxide percentage.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Typo correction.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	D	[REDACTED]	06-23-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested regarding use of tattooing.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
27. # [REDACTED]	C	[REDACTED]	06-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. # [REDACTED]	D Y	[REDACTED]	06-09-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of **229** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies,

and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	06-30-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Reviewer													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	15												
2. # [REDACTED]	C	[REDACTED]	06-27-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Reviewer													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	15												
3. # [REDACTED]	D Y	[REDACTED]											
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	15												
4. # [REDACTED]	D Y	[REDACTED]	06-24-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Confirmed SCRO. b. IACUC Staff made wording changes as directed at IACUC meeting for approval. c. DMR pending Chem approval: completed; Add VHSSs Additional discussion during the meeting included: a. Reviewer requested additional review time. Approved for DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0		
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												

	Present	15	
5. #	D Y		06-24-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Confirmed SCRO. b. IACUC Staff made wording changes as directed at IACUC meeting for approval. c. DMR pending Chem approval: completed; Add VHSSs <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Reviewer requested additional review time. Approved for DMR. <div style="border: 1px solid black; padding: 5px; margin: 5px 0;"> <p style="text-align: center;">IACUC Vote</p> <p>Approval 0</p> <p>Withhold Approval 0</p> <p>Abstain 0</p> <p>Present 15</p> </div>			
6. #	C		06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. <div style="border: 1px solid black; padding: 5px; margin: 5px 0;"> <p style="text-align: center;">IACUC Vote</p> <p>Approval 15</p> <p>Withhold Approval 0</p> <p>Abstain 0</p> <p>Present 15</p> </div>			
7. #	D		06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarified animal numbers and VHSS attachments. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. <div style="border: 1px solid black; padding: 5px; margin: 5px 0;"> <p style="text-align: center;">IACUC Vote</p> <p>Approval 15</p> <p>Withhold Approval 0</p> <p>Abstain 0</p> <p>Present 15</p> </div>			
8. #	D		06-23-2022
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification on euthanasia criteria. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. <div style="border: 1px solid black; padding: 5px; margin: 5px 0;"> <p style="text-align: center;">IACUC Vote</p> <p>Approval 15</p> <p>Withhold Approval 0</p> <p>Abstain 0</p> </div>			

	Present	15											
9. #	D		06-23-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI clarified numbers justification and risk of hyper and hypoglycemia added to adverse effects. Chemical safety officer completed review and updated Tamoxifen VHSS. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>14</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	14	Withhold Approval	0	Abstain	1	Present	15
IACUC Vote													
Approval	14												
Withhold Approval	0												
Abstain	1												
Present	15												
10. #	D		06-23-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI submitted a PI maintain form and updated room log and SOPs. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>14</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	14	Withhold Approval	0	Abstain	1	Present	15
IACUC Vote													
Approval	14												
Withhold Approval	0												
Abstain	1												
Present	15												
11. #	D Y												
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI requested to provide a summary to clarify the surgeries. Additional discussion during the meeting included: a. Committee voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	15												
12. #	D		06-23-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI attached a client consent form for personal animals. Discussed adding consent forms to all protocols (not just clinical trails) moving forward until our updated MOU policy is approved. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>14</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>14</td></tr></table>				IACUC Vote		Approval	14	Withhold Approval	0	Abstain	0	Present	14
IACUC Vote													
Approval	14												
Withhold Approval	0												
Abstain	0												
Present	14												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		07-08-2020	06-23-2022	07-08-2023
	D		06-25-2020	06-23-2022	06-25-2023
	D Y		06-29-2020	06-23-2022	06-29-2023
	C Y		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	D Y		06-25-2020	06-23-2022	06-25-2023
	E		06-25-2020	06-23-2022	06-25-2023
	C Y		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	C		07-06-2020	06-23-2022	07-06-2023
	C		06-25-2020	06-23-2022	06-25-2023
	C		06-25-2020	06-23-2022	06-25-2023
	D Y		06-25-2020	06-23-2022	06-25-2023
	C		07-08-2020	06-23-2022	07-08-2023
	D Y		07-08-2021	06-23-2022	07-08-2023
	D Y		07-08-2021	06-23-2022	07-08-2023
	C		06-23-2021	06-23-2022	06-23-2023
	C		07-07-2021	06-23-2022	07-07-2023
	C		07-08-2021	06-23-2022	07-08-2023
	D		07-01-2021	06-23-2022	07-01-2023
	C Y		06-28-2021	06-23-2022	06-28-2023
	D Y		07-05-2021	06-23-2022	07-05-2023

	C		7-07-2021	06-23-2022	07-07-2023
	D		7-08-2021	06-23-2022	07-08-2023
	D		7-08-2021	06-23-2022	07-08-2023
	D Y		6-25-2021	06-23-2022	06-25-2023
	C		7-08-2021	06-23-2022	07-08-2023
	C		7-08-2021	06-23-2022	07-08-2023

Discussion:	<p>██████████ and ██████████ - updated genotyping policy sent to PI and alternate contact.</p> <p>██████████ - Field study protocol not currently active and PI is out of state. Some administrative amendments are needed to update staff, training and permit.</p> <p>██████████ permit on protocol is expired. PI provided updated permit.</p> <p>██████████ updated literature search needed for approved amendment.</p> <p>IACUC staff working with PI.</p>										
Action Items:	<p>██████████ and ██████████ PI to updated protocol as needed with an amendment and training for staff.</p> <p>██████████ - committee approved renewal since IACUC staff is working with PI to update the protocol.</p> <p>██████████ - committee approved updating the protocol with the updated permit information.</p> <p>██████████ committee approved renewal since IACUC staff is working with PI on getting the amendment submitted.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>14</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>14</td></tr> </tbody> </table>		IACUC Vote		Approval	14	Withhold Approval	0	Abstain	0	Present	14
IACUC Vote											
Approval	14										
Withhold Approval	0										
Abstain	0										
Present	14										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	06-23-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. All question addressed during the pre-review process. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>15</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	15												
Withhold Approval	0												
Abstain	0												
Present	15												

2. #	C		06-23-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>15</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	15												
Withhold Approval	0												
Abstain	0												
Present	15												
3. #	D		06-23-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed changing protocol category from C to D. Additional discussion during the meeting included: a. Approved change from C to D.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>14</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	14	Withhold Approval	0	Abstain	1	Present	15
IACUC Vote													
Approval	14												
Withhold Approval	0												
Abstain	1												
Present	15												
4. #	D		06-23-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Voted to Approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>14</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	14	Withhold Approval	0	Abstain	1	Present	15
IACUC Vote													
Approval	14												
Withhold Approval	0												
Abstain	1												
Present	15												
5. #	C		06-23-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>15</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>				IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote													
Approval	15												
Withhold Approval	0												
Abstain	0												
Present	15												
6. #	D		06-23-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr></table>				IACUC Vote									
IACUC Vote													

		Approval	15		
		Withhold Approval	0		
		Abstain	0		
		Present	15		
7. #		D Y			06-23-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:					
a. Timeframe context added.					
Additional discussion during the meeting included:					
a. None.					
		IACUC Vote			
		Approval	15		
		Withhold Approval	0		
		Abstain	0		
		Present	15		
8. #		D Y			07-07-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:					
a. Future situation prevention measures.					
b. Need for replacement animal.					
Additional discussion during the meeting included:					
a. Pending PI. Approved for DMR.					
		IACUC Vote			
		Approval	0		
		Withhold Approval	0		
		Abstain	0		
		Present	15		
9. #		D			06-23-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:					
a. Clarification of request for additional animals.					
Additional discussion during the meeting included:					
a. None.					
		IACUC Vote			
		Approval	15		
		Withhold Approval	0		
		Abstain	0		
		Present	15		
10. #		D			06-23-2022
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:					
a. None.					
Additional discussion during the meeting included:					
a. None.					
		IACUC Vote			
		Approval	14		
		Withhold Approval	0		
		Abstain	1		
		Present	15		

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 01-27-2022	
2. 01-28-2022	
3. 02-25-2022	
4. 03-02-2022	
5. 05-12-2022	
6. 05-26-2022	
7. 05-31-2022	
8. 06-16-2022	

Discussion: 5- normal wear and tear of building. One eyewash station was missed during facility inspection.
 7- normal wear and tear of building.
 8- inspection was of personal vehicle being used to transport animals from vendor.

Action: 5- normal wear and tear of building.
 7- normal wear and tear of building.
 8- vehicle approved for transport.

IACUC Vote

Approval	14
Withhold Approval	0
Abstain	0
Present	14

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 05-16-2022	LAB	
2. 05-19-2022	LAB	
3. 05-24-2022	LAB	
4. 05-27-2022	PAM	

Discussion: None.

Action: None.

IACUC Vote

Approval	15
Withhold Approval	0
Abstain	0
Present	15

XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:

Inspection Date	Agency	Location	Summary	Discussion
1. 06-22-2022	USDA	Site 1, vivaria and records	No Non-compliant items.	High standard expectation.

2. 06-23-2022	USDA	Site 1, vivaria and records	No non-compliant items.	High standard expectation.
------------------	------	-----------------------------	-------------------------	----------------------------

XV. Other Discussion Items:

Topic	
1. Guest - [REDACTED]	
Discussion:	2nd meeting attended for MS program.
Action:	IACUC director to provide documentation of attendance.
2. PI maintain form = Psychology Field Pens	
Discussion:	PI maintain area has existed prior to the PI maintain policy. This PI maintain form is to ensure consistency with program.
Action:	Committee approved form.
5 [REDACTED] last meeting	
Discussion:	IACUC thanked [REDACTED] for his lengthy tenure and valued service on the IACUC.
Action:	None.
IACUC-28 "Humane Endpoints for Laboratory Animals"	
Discussion:	None.
Action:	Tabled.
IACUC-37 "Guidelines for Euthanasia of Research and Teaching Animals"	
Discussion:	None.
Action:	Tabled.
PI Maintained Dairy Calves at [REDACTED]	
Discussion:	None.
Action:	Approved.
PI Maintained: [REDACTED] Fish	
Discussion:	None.
Action:	Approved.
[REDACTED], PI maintained forms, currently and historically PI maintained, just updating paperwork.	
Discussion:	None.
Action:	Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.